EP2217701B9 - Antagonistes du glucagon - Google Patents

Antagonistes du glucagon Download PDF

Info

Publication number
EP2217701B9
EP2217701B9 EP08845852.6A EP08845852A EP2217701B9 EP 2217701 B9 EP2217701 B9 EP 2217701B9 EP 08845852 A EP08845852 A EP 08845852A EP 2217701 B9 EP2217701 B9 EP 2217701B9
Authority
EP
European Patent Office
Prior art keywords
glucagon
seq
amino acid
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP08845852.6A
Other languages
German (de)
English (en)
Other versions
EP2217701B1 (fr
EP2217701A4 (fr
EP2217701A2 (fr
Inventor
Richard D. Dimarchi
Bin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of EP2217701A2 publication Critical patent/EP2217701A2/fr
Publication of EP2217701A4 publication Critical patent/EP2217701A4/fr
Publication of EP2217701B1 publication Critical patent/EP2217701B1/fr
Application granted granted Critical
Publication of EP2217701B9 publication Critical patent/EP2217701B9/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Native glucagon is a 29 amino acid peptide that regulates blood glucose levels through enhanced synthesis and mobilization of glucose in the liver. Consequently, the suppression of endogenous glucagon action has been a target for the development of drugs to treat conditions characterized by excessive glucose production, such as diabetes.
  • Glucagon generally functions as a counter-regulatory hormone, opposing the actions of insulin, to maintain the level of blood glucose, particularly in instances of hypoglycemia.
  • absolute or relative elevated glucagon levels have been shown to contribute to the hyperglycemic state.
  • removal of circulating glucagon with selective and specific antibodies has resulted in reduction of the glycemic level ( Brand et al., Diabetologia 37, 985 (1994 ); Diabetes 43, [suppl 1], 172A (1994 ); Am. J. Physiol. 269, E469-E477 (1995 ); Diabetes 44 [suppl 1], 134A (1995 ); Diabetes 45, 1076 (1996 )).
  • Glucagon exerts its action by binding to and activating its receptor, which is part of the glucagon-secretin branch of the 7-transmembrane G-protein coupled receptor family.
  • the receptor functions by an activation of the adenylyl cyclase resulting in increased cAMP levels.
  • Previous reports have identified peptide-based, (see Unson, C. G. et al. (1989) J. Biol. Chem. 264, 789-94 , Ahn, J. et al. (2001) J. Peptide Research 58, 151-8 and Ahn J. et al. (2001) J. Med. Chem.
  • nucleotide-based glucagon antagonists Sloop K. et al. (2004) J. Clinical Invest. 113, 1571-81 .
  • Peptide-based inhibition acts at the level of receptor binding while the latter functions by suppressing intracellular mRNA specific to the glucagon receptor.
  • Inhibitors of the glucagon receptor have been described, and are generally based on the amino acid sequence of glucagon.
  • Several analogues in which one or more amino acids were either deleted or substituted to produce potent antagonists of glucagon receptor have been described, for example, [des His 1 ] [Glu 9 ]-glucagon amide ( Unson et al., (1989) Peptides 10, 1171 ; Post et al., (1993) Proc. Natl. Acad. Sci. USA 90, 1662 ), des His 1 , Phe 6 [Glu9]-glucagon amide ( Azizh et al., (1995) Bioorg. & Med. Chem. Lett.
  • high potency glucagon antagonists are provided that represent modifications of the native glucagon peptide. More particularly, the novel glucagon antagonist represent novel chemical modifications of the N-terminus of the native glucagon sequence, producing a highly specific antagonist that exhibits no apparent agonist activity. These compounds can be used in any setting where the suppression of glucagon agonism is desired. In accordance with one embodiment the compounds can be used in the treatment of diabetes.
  • analogs of glucagon are provided that have pure glucagon antagonist activities.
  • the glucagon antagonists would be used in any setting where the suppression of glucagon agonism is desired. The most immediate and obvious use would be in the treatment of diabetes where glucagon antagonism has been demonstrated in pre-clinical models of hyperglycemia to yield a lowering of blood glucose.
  • These glucagon antagonists can be further modified to improve the biophysical stability and/or aqueous solubility of the compounds while maintaining the antagonist activity of the parent compound.
  • a glucagon antagonist comprising a native glucagon peptide that has been modified by the deletion of the first 2 - 5 amino acids residues from the N-terminus, and a substitution of the aspartic acid at position 9 of the native peptide with an amino acid selected from the group consisting of glutamic acid, homoglutamic acid, ⁇ -homoglutamic acid, a sulfonic acid derivative of cysteine, or an alkylcarboxylate derivative of cysteine having the structure of: wherein X 5 is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, or C 2 -C 4 alkynyl.
  • the sulfonic acid derivative of cysteine is cysteic acid or homocysteic acid.
  • the natural carboxylic acid of the C-terminal amino acid is replaced with a charge-neutral group, such as an amide or ester.
  • a glucagon antagonist comprising a native glucagon peptide that has been modified by the deletion of the first 5 amino acids residues from the N-terminus, and modification of the remaining N-terminal amino acid (phenylalanine) to replace the native N-terminal amino group with a hydroxyl group (i.e., an N-terminal phenyl-lactic acid (PLA)).
  • the PLA6 analog increases the affinity threefold, and the potency of antagonism, relative to an analog that comprises a deletion of the first five amino acids but retains the N-terminal native phenyalanine.
  • the aspartic acid residue at position nine of the native protein is constituted with an amino acid selected from the group consisting of aspartic acid, glutamic acid, homoglutamic acid, ⁇ -homoglutamic acid, a sulfonic acid derivative of cysteine, or an alkylcarboxylate derivative of cysteine having the structure of: wherein X 5 is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, or C 2 -C 4 alkynyl.
  • the glucagon antagonist comprises a sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 36, SEQ ID NO: 37 and SEQ ID NO: 38, and in one embodiment the glucagon antagonist comprises the sequence of SEQ ID NO: 7 or 8.
  • a glucagon antagonist comprising the sequence of SEQ ID NO: 7 or SEQ ID NO: 37 wherein a polyethylene glycol chain is covalently linked to an amino acid at position 11, 12, 16, 19 or 24, or at the N- or C-terminal amino acid of the peptide.
  • a glucagon antagonist is provided comprising the sequence of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein a polyethylene glycol chain is covalently linked to an amino acid at position 11 of SEQ ID NO: 9, position 16 of SEQ ID NO: 10, position 19 of SEQ ID NO: 11 or at both positions 11 and 19 for SEQ ID NO: 12.
  • a single polyethylene glycol chain having a molecular weight selected from the range of about 1,000 to about 5,000 Daltons is covalently bound to the glucagon antagonist peptide.
  • a single polyethylene glycol chain having a molecular weight of at least about 20,000 Daltons is covalently bound to the glucagon antagonist peptide.
  • the glucagon antagonist comprises the sequence of SEQ ID NO: 12 and has a polyethylene glycol chain covalently bound to both amino acid position 11 and 19, wherein the combined molecular weight of the two polyethylene chains is either about 1,000 to about 5,000 Daltons or is greater than about 20,000 Daltons.
  • a glucagon antagonist wherein the carboxy terminal amino acid of the peptide of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 36, SEQ ID NO: 39 or SEQ ID NO: 40 is covalently bound to a second peptide comprising the sequence of SEQ ID NO: 19 (GPSSGAPPPS).
  • GPSSGAPPPS the sequence of SEQ ID NO: 19
  • These compounds may be further modified by the covalent linkage of a PEG group to the glucagon analog at a position selected from 11, 16, 19 for SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 36, SEQ ID NO: 39 or SEQ ID NO: 40.
  • a glucagon antagonist wherein the carboxy terminal amino acid of the peptide of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 36, SEQ ID NO: 39 or SEQ ID NO: 38 is covalently bound to a second peptide comprising the sequence of SEQ ID NO: 53.
  • the glucagon antagonist comprises the structure A-B-C as described herein, wherein
  • any of the preceding glucagon antagonists which lacks one to five N-terminal amino acids of native glucagon and/or comprises PLA can be improved by modifying the peptide by substitutions and/or additions that introduce a charged amino acid into the C-terminal portion of the peptide, preferably at a position C-terminal to position 22 of the glucagon antagonist.
  • one, two or three charged amino acids may be introduced within the C-terminal portion, preferably C-terminal to position 22 (position 27 of native glucagon).
  • the native amino acid(s) at positions 23 and/or 24 are substituted with a charged amino acid, and/or in a further embodiment one to three charged amino acids are also added to the C-terminus of the peptide. In exemplary embodiments, one, two or all of the charged amino acids are negatively charged.
  • the glucagon antagonist of SEQ ID NO: 7 or SEQ ID NO: 8 is further modified to include an acidic amino acid substitution at position 23 and/or 24.
  • the acidic amino acid is an aspartic acid or glutamic acid residue, and the glucagon antagonist comprises the sequence of SEQ ID NO: 41.
  • the stability of the glucagon antagonists which lack amino acids 1-5 of native glucagon and/or comprises PLA at physiological pH can be improved by substituting the aspartic acid residue at position 10 (position 15 of native glucagon) with an amino acid selected from the group consisting of Glu, cysteic acid, homoglutamic acid or homocysteic acid.
  • a glucagon antagonist comprises the sequence of SEQ ID NO: 36 or SEQ ID NO: 40.
  • any of the glucagon antagonists described herein may be further modified to comprise one or more ⁇ , ⁇ -disubstituted amino acids at positions that retain the desired activity.
  • one, two, three, four or more of positions 16, 17, 18, 20, 21, 24 or 29 (according to the amino acid numbering of wild type glucagon) of the glucagon antagonist is substituted with an ⁇ , ⁇ -disubstituted amino acid.
  • the glucagon antagonist can comprise a substitution of position 16 (according to the amino acid numbering of wild type glucagon) with amino iso-butyric acid (AIB).
  • one, two, three or more of positions 16, 20, 21 or 24 are substituted with AIB.
  • the glucagon antagonist comprising one or more ⁇ , ⁇ -disubstituted amino acids further comprises a C-terminal carboxylate.
  • glucagon antagonists described herein may be further modified to comprise an acyl group and/or an alkyl group, which acyl or alkyl group is attached to an amino acid of a spacer or the glucagon antagonist via an ester, ether, thioether, amide, or alkyl amine linkage, as described herein.
  • glucagon antagonists described herein may be further modified by truncation or deletion of one or two amino acids of the C-terminus of the glucagon peptide (i.e., position 29 or positions 28 and 29 of the native glucagon peptide).
  • glucagon analogs disclosed herein can be further modified to comprise up to 2, 3, 4, 5, 6, 7, 8 or 9 further amino acid modifications, and still retain the desired level of activity of a glucagon antagonist at the glucagon receptor.
  • glucagon antagonist dimer comprising two peptides independently selected form the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39 and SEQ ID NO: 40, wherein the two glucagon antagonists are bound to one another through a linker independently bound to position 11 or 19 of the respective peptide chains.
  • a pharmaceutical composition comprising the novel glucagon antagonists disclosed herein.
  • the pharmaceutical compositions comprise solutions that are sterilized and contained within various packages.
  • the pharmaceutical compositions can be further packaged as part of a kit that includes a disposable device for administering the composition to a patient.
  • a method of rapidly treating hyperglycemia using a pre-formulated aqueous composition comprises the step of administering an effective amount of an aqueous solution comprising a novel modified glucagon antagonist of the present disclosure.
  • the glucagon antagonist is pegylated and the PEG chain has a molecular weight of about 500 to about 5,000 Daltons.
  • the modified glucagon solution is prepackaged in a device that is used to administer the composition to the patient suffering from hyperglycemia.
  • an improved method of regulating blood glucose levels in insulin dependent patients comprises the steps of administering insulin in an amount therapeutically effective for the control of diabetes and administering a novel modified glucagon antagonist of the present disclosure, wherein said administering steps are conducted within twelve hours of each other.
  • the glucagon antagonist and the insulin are co-administered as a single composition, wherein the glucagon peptide is pegylated with a PEG chain having a molecular weight selected from the range of about 5,000 to about 40,000 Daltons.
  • the term "pharmaceutically acceptable carrier” includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.
  • the term also encompasses any of the agents approved by a regulatory agency of the US Federal government or listed in the US Pharmacopeia for use in animals, including humans.
  • pharmaceutically acceptable salt refers to salts of compounds that retain the biological activity of the parent compound, and which are not biologically or otherwise undesirable. Many of the compounds disclosed herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases.
  • Salts derived from inorganic bases include by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines.
  • Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
  • treating includes prophylaxis of the specific disorder or condition, or alleviation of the symptoms associated with a specific disorder or condition and/or preventing or eliminating said symptoms.
  • an "effective" amount or a “therapeutically effective amount” of a glucagon antagonist refers to a nontoxic but sufficient amount of the peptide to provide the desired effect.
  • one desired effect would be the prevention or treatment of hyperglycemia.
  • the amount that is "effective” will vary from subject to subject, depending on the age and general condition of the individual, mode of administration, and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
  • parenteral means not through the alimentary canal but by some other route such as subcutaneous, intramuscular, intraspinal, or intravenous.
  • a "glucagon peptide” as used herein includes any peptide comprising, either the amino acid sequence of SEQ ID NO: 1, or any derivative of the amino acid sequence of SEQ ID NO: 1, including amino acid substitutions, or post translational modifications (e.g. methylation, acylation, ubiquitination and the like) of the peptide, that stimulates glucagon or GLP-1 receptor activity, as measured by cAMP production using the assay described in Example 13.
  • glucagon antagonist refers to a compound that counteracts glucagon activity or prevents glucagon function.
  • a glucagon antagonist exhibits at least 60% inhibition (e.g., at least 70% inhibition) and preferably, at least 80% inhibition, of the maximum response achieved by glucagon at the glucagon receptor.
  • the glucagon antagonist exhibits at least 90% inhibition of the maximum response achieved by glucagon at the glucagon receptor.
  • the glucagon antagonist exhibits 100% inhibition of the maximum response achieved by glucagon at the glucagon receptor.
  • a glucagon antagonist at a concentration of about 1 ⁇ M exhibits less than about 20% of the maximum agonist activity achieved by glucagon at the glucagon receptor. In one embodiment, the glucagon antagonist exhibits less than about 10% of the maximum agonist activity achieved by glucagon at the glucagon receptor. In a specific embodiment, the glucagon antagonist exhibits less than about 5% of the maximum agonist activity achieved by glucagon at the glucagon receptor. In yet another specific embodiment, the glucagon antagonist exhibits 0% of the maximum agonist activity achieved by glucagon at the glucagon receptor.
  • a "pure glucagon antagonist” is a glucagon antagonist that does not produce any detected stimulation of glucagon or GLP-1 receptor activity, as measured by cAMP production using a validated in vitro model assay, such as that described in Example 13.
  • a pure glucagon antagonist exhibits less than about 5% (e.g., less than about 4%, less than about 3%, less than about 2%, less than about 1%, about 0%) of the maximum agonist activity achieved by glucagon at the glucagon receptor and exhibits less than about 5% (e.g., less than about 4%, less than about 3%, less than about 2%, less than about 1%, and about 0%) of the maximum agonist activity achieved by GLP-1 at the GLP-1 receptor.
  • a "derivative glucagon antagonist” is a peptide that shares greater than 60% amino acid sequence identity with the amino acid of SEQ ID NO: 1, but has been modified to exhibit glucagon antagonist activity. Such modifications include amino acid substitutions or deletions, or post translational modifications (e.g. methylation, amidation, acylation, ubiquitination, pegylation and the like) of the peptide.
  • a derivative glucagon antagonist comprises the glucagon peptide of SEQ ID NO: 1 that has been modified to have the first five amino acid residues deleted from the N-terminus, and has the amino group of the remaining N-terminal amino acid (phenylalanine) substituted with a hydroxyl group.
  • an amino acid "modification” refers to a substitution, addition or deletion of an amino acid, and includes substitution with or addition of any of the 20 amino acids commonly found in human proteins, as well as atypical or non-naturally occurring amino acids.
  • Commercial sources of atypical amino acids include Sigma-Aldrich (Milwaukee, WI), ChemPep Inc. (Miami, FL), and Genzyme Pharmaceuticals (Cambridge, MA).
  • Atypical amino acids may be purchased from commercial suppliers, synthesized de novo, or chemically modified or derivatized from naturally occurring amino acids.
  • substitution refers to the replacement of one amino acid residue by a different amino acid residue.
  • polyethylene glycol refers to mixtures of condensation polymers of ethylene oxide and water, in a branched or straight chain, represented by the general formula H(OCH 2 CH 2 ) n OH, wherein n is at least 9. Absent any further characterization, the term is intended to include polymers of ethylene glycol with an average total molecular weight selected from the range of 500 to 40,000 Daltons. "Polyethylene glycol” or “PEG” is used in combination with a numeric suffix to indicate the approximate average molecular weight thereof. For example, PEG-5,000 refers to polyethylene glycol having a total molecular weight average of about 5,000.
  • pegylated and like terms refers to a compound that has been modified from its native state by linking a polyethylene glycol polymer to the compound.
  • a "pegylated glucagon antagonist” is a glucagon antagonist that has a PEG chain covalently bound to the glucagon antagonist.
  • a general reference to a peptide is intended to encompass peptides that have modified amino and carboxy termini.
  • an amino acid chain comprising an amide group in place of the terminal carboxylic acid is intended to be encompassed by an amino acid sequence designating the standard amino acids.
  • Linker is a bond, molecule or group of molecules that binds two separate entities to one another. Linkers may provide for optimal spacing of the two entities or may further supply a labile linkage that allows the two entities to be separated from each other. Labile linkages include photocleavable groups, acid-labile moieties, base-labile moieties and enzyme-cleavable groups.
  • a "dimer” is a complex comprising two subunits covalently bound to one another via a linker.
  • dimer when used absent any qualifying language, encompasses both homodimers and heterodimers.
  • a homodimer comprises two identical subunits, whereas a heterodimer comprises two subunits that differ, although the two subunits are substantially similar to one another.
  • charged amino acid refers to an amino acid that comprises a side chain that is negatively charged (i.e., de-protonated) or positively charged (i.e., protonated) in aqueous solution at physiological pH.
  • negatively charged amino acids include aspartic acid, glutamic acid, cysteic acid, homocysteic acid, and homoglutamic acid
  • positively charged amino acids include arginine, lysine and histidine.
  • Charged amino acids include the charged amino acids among the 20 amino acids commonly found in human proteins, as well as atypical or non-naturally occurring amino acids.
  • sulfonic acid derivative of cysteine refers to compounds of the general structure: wherein X 6 is C 1 -C 4 alkyl, C 2 -C 4 alkene or C 2 -C 4 alkynyl.
  • C 1 -C n alkyl wherein n can be from 1 through 6, as used herein, represents a branched or linear alkyl group having from one to the specified number of carbon atoms.
  • Typical C 1 -C 6 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl and the like.
  • C 2 -C n alkenyl wherein n can be from 2 through 6, as used herein, represents an olefinically unsaturated branched or linear group having from 2 to the specified number of carbon atoms and at least one double bond.
  • C 2 -C n alkynyl wherein n can be from 2 to 6, refers to an unsaturated branched or linear group having from 2 to n carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, and the like.
  • pH stabilized glucagon antagonist refers to a glucagon analog that exhibits superior stability and solubility, relative to native glucagon, in aqueous buffers in the broadest pH range used for pharmacological purposes.
  • acidic amino acid refers to an amino acid that comprises a second acidic moiety, including for example, a carboxylic acid or sulfonic acid group.
  • patient without further designation is intended to encompass any warm blooded vertebrate domesticated animal (including for example, but not limited to livestock, horses, cats, dogs and other pets) and humans.
  • glucagon antagonists that are highly specific to glucagon suppression and possess no apparent agonist activity. Such glucagon antagonists are utilized in any setting where the suppression of glucagon's agonism is desired. For example glucagon antagonists can be used in the treatment of diabetes where glucagon antagonism has been demonstrated in pre-clinical models of hyperglycemia to yield a lowering of blood glucose.
  • glucagon derivatives having sulfonic acid substituents substituted at amino acid position nine of glucagon perform similarly to the carboxylic acid-based amino acids but with a few critical differences in relation to physical properties such as solubility.
  • N-terminal residues including for example, the removal of the first five amino acids (yielding des(1-5), and substitution of position 9 (according to the numbering of SEQ ID NO: 1) with hCys(SO 3 ), homoglutamic acid, ⁇ -homoglutamic acid, or an alkylcarboxylate derivative of cysteine having the structure of: wherein X 5 is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, or C 2 -C 4 alkynyl, provides a compound that performs as a hormonal antagonist that is highly specific, potent and without contaminating agonist properties.
  • glucagon derivative peptides that exhibit pure glucagon antagonist activity are disclosed herein.
  • the glucagon antagonist exhibits activity that reduces glucagon receptor glucagon-induced cAMP production by a maximum of at least 50% when the glucagon receptor is contacted simultaneously with 0.8nM of glucagon and the glucagon antagonist, as measured by cAMP production in an in vitro assay.
  • the glucagon antagonist reduces glucagon receptor glucagon-induced cAMP production by a maximum amount of at least 80%.
  • a derivative glucagon antagonist comprises a glucagon peptide modified, relative to the wild type sequence of SEQ ID NO: 1, by the deletion of two to five amino acid residues from the N-terminus and substitution of the aspartic acid residue at position nine of the native protein with a glutamic acid, homoglutamic acid, ⁇ -homoglutamic acid, a sulfonic acid derivative of cysteine, or an alkylcarboxylate derivative of cysteine having the structure of: wherein X 5 is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, or C 2 -C 4 alkynyl.
  • the glucagon antagonist comprising the deletion of two to five amino acid residues from the N-terminus and substitution of the Asp at position 9 of the native glucagon, is further modified by up to three amino acid modifications.
  • the glucagon antagonist may comprise one, two, or three conservative amino acid modifications.
  • the glucagon antagonist may comprise one or more amino acid modifications selected from the group consisting of:
  • the glucagon antagonist comprises an amino acid modification of A, B, or C, as described above, or a combination thereof.
  • the glucagon antagonist further comprises an amino acid modification of any of D to K as described above, or a combination thereof, in addition to the amino acid modification(s) of A, B, and/or C.
  • the glucagon antagonist comprises a glucagon peptide, wherein the first 5 amino acids have been removed from the N-terminus, and the remaining N-terminal amino group has been replaced with a hydroxyl group (the "PLA6 analog"), producing the peptide of SEQ ID NO: 39.
  • PPA6 analog a hydroxyl group
  • substitution of phenyl-lactic acid for phenylalanine in glucagon antagonist analogs that have the first five amino acids deleted and substitution of a glutamic acid at position 9 (relative to native glucagon) further enhances the potency of those glucagon antagonist analogs.
  • the glucagon antagonist peptide of SEQ ID NO: 39 is further modified by substituting the aspartic acid residue at position four (position 9 of the native glucagon) with an amino acid of the general structure: wherein X 6 is C 1 -C 3 alkyl, C 2 -C 3 alkene or C 2 -C 3 alkynyl, and in one embodiment X is C 1 -C 3 alkyl, and in another embodiment X is C 2 alkyl.
  • the glucagon antagonist comprises a glucagon peptide, wherein the first 5 amino acids have been removed from the N-terminus, and the aspartic acid residue at position four (position 9 of the native glucagon) has been substituted with cysteic acid or homocysteic acid.
  • the glucagon antagonist comprises a glucagon peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 7 and SEQ ID NO: 8.
  • the glucagon antagonist comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 8, wherein the amino acid at position four is homocysteic acid.
  • the glucagon antagonist of SEQ ID NO: 39 is further modified by substituting the aspartic acid residue at position four (position 9 of the native glucagon) with glutamic acid, homoglutamic acid, ⁇ -homoglutamic acid, or an alkylcarboxylate derivative of cysteine having the structure of: wherein X 5 is C 1 -C 4 alkyl, C 2 -C 4 alkenyl, or C 2 -C 4 alkynyl. In a specific embodiment, X is C 1 or C 2 alkyl.
  • the PLA6 analog is an appreciably more potent antagonist than glucagon analogs having a slightly extended N-terminus (see the results presented in Table 8 and Fig. 8 ).
  • the results presented in Fig. 8 also demonstrate that acylation of the PLA hydroxy group does not affect PLA6 analog potency. Accordingly, the present invention also includes analogs wherein the N-terminal amino group is substituted with an acylated and alkylated "O-terminal" peptides.
  • the PLA6 substitution not only increases the potency of the antagonist but also serves a critical role in pegylation.
  • the PLA6 analogs can be selectively pegylated without restoration of glucagon agonism.
  • pegylation of the analog surprisingly induces glucagon agonism.
  • This glucagon agonism is not seen in the pegylated PLA6 analogs.
  • Several sites for pegylation were investigated including positions 3, 6 and 19 (positions 8, 11 and 19 of native glucagon) and at the N-terminal amino acid residue (see Table 12). In one embodiment the pegylation is at position 19 (position 24 of native glucagon) as that site exhibits the most potent and selective glucagon antagonism.
  • the glucagon antagonist comprises the general structure of A-B-C, wherein
  • the glucagon antagonist comprises an oxy derivative of PLA.
  • oxy derivative of PLA refers to a compound comprising a modified structure of PLA in which the hydroxyl group has been replaced with O-R 11 , wherein R 11 is a chemical moiety.
  • the oxy derivative of PLA can be, for example, an ester of PLA or an ether of PLA.
  • the ester may be formed by upon reaction of the hydroxyl of PLA with a carbonyl bearing a nucleophile.
  • the nucleophile can be any suitable nucleophile, including, but not limited to an amine or hydroxyl.
  • the ester of PLA can comprise the structure of Formula IV: wherein R7 is an ester formed upon reaction of the hydroxyl of PLA with a carbonyl bearing a nucleophile.
  • the carbonyl bearing a nucleophile (which reacts with the hydroxyl of PLA to form an ester) can be, for example, a carboxylic acid, a carboxylic acid derivative, or an activated ester of a carboxylic acid.
  • the carboxylic acid derivative can be, but is not limited to, an acyl chloride, an acid anhydride, an amide, an ester, or a nitrile.
  • the activated ester of a carboxylic acid can be, for example, N-hydroxysuccinimide (NHS), tosylate (Tos), a carbodiimide, or a hexafluorophosphate.
  • the carbodiimide is 1,3-dicyclohexylcarbodiimide (DCC), 1,1'-carbonyldiimidazole (CDI), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), or 1,3-diisopropylcarbodiimide (DICD).
  • DCC 1,3-dicyclohexylcarbodiimide
  • CDI 1,1'-carbonyldiimidazole
  • EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
  • DICD 1,3-diisopropylcarbodiimide
  • the hexafluorophosphate is selected from a group consisting of hexafluorophosphate benzotriazol-1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), benzotriazol-1-yl- oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate (HATU), and o-benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU).
  • BOP benzotriazol-1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate
  • PyBOP benzotriazol-1-yl- oxytripyrrolidinophosphonium
  • ethers from reaction with a hydroxyl group e.g., the hydroxyl of PLA
  • a hydroxyl group of PLA may be reacted with a halogenated alkyl or tosylated alkyl alcohol to form an ether bond.
  • the chemical moiety of R 11 is one which does not decrease the activity of the glucagon antagonist. In some embodiments, the chemical moiety enhances the activity, stability, and/or solubility of the glucagon antagonist.
  • the chemical moiety bound to PLA via an oxygen-containing bond is a polymer (e.g., a polyalkylene glycol), a carbohydrate, an amino acid, a peptide, or a lipid, e.g., a fatty acid or a steroid.
  • the chemical moiety is an amino acid, which, optionally, is a part of a peptide, such that Formula IV is a depsipeptide.
  • PLA may be at a position other than the N-terminal amino acid residue of the glucagon antagonist, such that the glucagon antagonist comprises one or more (e.g., 1, 2, 3, 4, 5, 6, or more) amino acids N-terminal to the PLA residue.
  • the glucagon antagonist can comprise PLA at position n, wherein n is 2, 3, 4, 5, or 6 of the glucagon antagonist.
  • the amino acids N-terminal to the PLA residue may be synthetic or naturally-occurring.
  • the amino acids which are N-terminal PLA are naturally-occurring amino acids.
  • the amino acids which are N-terminal to PLA are the N-terminal amino acids of native glucagon.
  • the glucagon antagonist can comprise at the N-terminus the amino acid sequence of any of SEQ ID NOs: 54-58, wherein PLA is linked to threonine via an ester bond:
  • one or more of the N-terminal amino acids may be substituted with an amino acid other than the amino acid of native glucagon.
  • the glucagon antagonist comprises PLA as the amino acid at position 5 or 6
  • the amino acid at position 1 and/or position 2 may be an amino acid which reduces susceptibility to cleavage by dipeptidyl peptidase IV.
  • position 1 of the glucagon antagonist is an amino acid selected from the group consisting of D-histidine, alpha, alpha-dimethyl imidiazole acetic acid (DMIA), N-methyl histidine, alpha-methyl histidine, imidazole acetic acid, desaminohistidine, hydroxyl-histidine, acetyl-histidine and homo-histidine.
  • position 2 of the antagonist peptide is an amino acid selected from the group consisting of D-serine, D-alanine, valine, glycine, N-methyl serine, N-methyl alanine, and aminoisobutyric acid (AIB).
  • the amino acid at position 3 of the glucagon antagonist may be glutamic acid, as opposed to the native glutamine residue of native glucagon.
  • the glucagon antagonist comprises at the N-terminus the amino acid sequence of any of SEQ ID NOs: 59-61.
  • the polymer may be any polymer, provided that it can react with the hydroxyl group of PLA.
  • the polymer may be one that naturally or normally comprises a carbonyl bearing a nucleophile.
  • the polymer may be one which was derivatized to comprise the carbonyl bearing the carbonyl.
  • the polymer may be a derivatized polymer of any of: polyamides, polycarbonates, polyalkylenes and derivatives thereof including, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polymers of acrylic and methacrylic esters, including poly(methyl methacrylate), poly(ethyl methacrylate), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate), polyvinyl polymers including polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, poly(vinyl acetate), and polyvinyl
  • the polymer can be a biodegradable polymer, including a synthetic biodegradable polymer (e.g., polymers of lactic acid and glycolic acid, polyanhydrides, poly(ortho)esters, polyurethanes, poly(butic acid), poly(valeric acid), and poly(lactide-cocaprolactone)), and a natural biodegradable polymer (e.g., alginate and other polysaccharides including dextran and cellulose, collagen, chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), albumin and other hydrophilic proteins (e.g., zein and other prolamines and hydrophobic proteins)), as well as any copolymer or mixture thereof.
  • these materials degrade either by enzymatic hydrolysis or exposure to water in vivo, by surface or bulk erosion.
  • the polymer can be a bioadhesive polymer, such as a bioerodible hydrogel described by H. S. Sawhney, C. P. Pathak and J. A. Hubbell in Macromolecules, 1993, 26, 581-587 , the teachings of which are incorporated herein, polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate).
  • a bioadhesive polymer such
  • the polymer is a water-soluble polymer.
  • Suitable water-soluble polymers include, for example, polyvinylpyrrolidone, hydroxypropyl cellulose (HPC; Klucel), hydroxypropyl methylcellulose (HPMC; Methocel), nitrocellulose, hydroxypropyl ethylcellulose, hydroxypropyl butylcellulose, hydroxypropyl pentylcellulose, methyl cellulose, ethylcellulose (Ethocel), hydroxyethyl cellulose, various alkyl celluloses and hydroxyalkyl celluloses, various cellulose ethers, cellulose acetate, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, vinyl acetate/crotonic acid copolymers, poly-hydroxyalkyl methacrylate, hydroxymethyl methacrylate, methacrylic acid copolymers, polymethacrylic acid, polymethylmethacrylate, maleic anhydride/methyl vinyl ether
  • the polymer is a polyalkylene glycol, including, for example, polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • the carbohydrate may be any carbohydrate provided that it comprises or is made to comprise a carbonyl with an alpha leaving group.
  • the carbohydrate for example, may be one which has been derivatized to comprise a carbonyl with an alpha leaving group.
  • the carbohydrate may be a derivatized form of a monosaccharide (e.g., glucose, galactose, fructose), a disaccharide (e.g., sucrose, lactose, maltose), an oligosaccharide (e.g., raffinose, stachyose), a polysaccharide (a starch, amylase, amylopectin, cellulose, chitin, callose, laminarin, xylan, mannan, fucoidan, galactomannan.
  • a monosaccharide e.g., glucose, galactose, fructose
  • a disaccharide
  • the lipid may be any lipid comprising a carbonyl with an alpha leaving group.
  • the lipid for example, may be one which is derivatized to comprise the carbonyl.
  • the lipid may be a derivative of a fatty acid (e.g., a C4-C30 fatty acid, eicosanoid, prostaglandin, leukotriene, thromboxane, N-acyl ethanolamine), glycerolipid (e.g., mono-, di-, trisubstituted glycerols), glycerophospholipid (e.g., phosphatidylcholine, phosphatidylinositol, phosphatidylethanolamine, phosphatidylserine), sphingolipid (e.g., sphingosine, ceramide), sterol lipid (e.g., steroid, cholesterol), prenol lipid, saccharolipid, or a polyketide. oil, wax, cholesterol, sterol, fat-soluble vitamin, monoglyceride, diglyceride, triglyceride, a phospholipid.
  • a fatty acid
  • R7 has a molecular weight of about 100 kDa or less, e.g., about 90 kDa or less, about 80 kDa or less, about 70 kDa or less, about 60 kDa or less, about 50 kDa or less, about 40 kDa or less. Accordingly, R7 can have a molecular weight of about 35 kDa or less, about 30 kDa or less, about 25 kDa or less, about 20 kDa or less, about 15 kDa or less, about 10 kDa or less, about 5 kDa or less, or about 1 kDa.
  • the glucagon antagonist comprises as A, a peptide of 2 to 6 amino acids in which two consecutive amino acids of the peptide are linked via an ester or ether bond.
  • the ester or ether bond may be, e.g., between amino acids 2 and 3, 3 and 4, 4 and 5, or 5 and 6.
  • the peptide may be further modified by covalent linkage to another chemical moiety including linkage to a polymer (e.g. a hydrophilic polymer), alkylation, or acylation.
  • the peptide may comprise any amino acids, synthetic or naturally occurring, provided that at least two consecutive amino acids of the peptide are linked via an ester or ether bond.
  • the peptide comprises amino acids of native glucagon.
  • the peptide can comprise j to 6 of native glucagon (SEQ ID NO: 1), wherein j is 1, 2, 3, 4, or 5.
  • the peptide can comprise an amino acid sequence based on the N-terminus of SEQ ID NO: 1 with one or more amino acid modifications.
  • the amino acid at position 1 and/or position 2 may be an amino acid which reduces susceptibility to cleavage by dipeptidyl peptidase IV.
  • the peptide can comprise at position 1 of the glucagon antagonist an amino acid selected from the group consisting of D-histidine, alpha, alpha-dimethyl imidiazole acetic acid (DMIA), N-methyl histidine, alpha-methyl histidine, imidazole acetic acid, desaminohistidine, hydroxyl-histidine, acetyl-histidine and homo-histidine.
  • position 2 of the antagonist peptide is an amino acid selected from the group consisting of D-serine, D-alanine, valine, glycine, N-methyl serine, N-methyl alanine, and aminoisobutyric acid (AIB).
  • the amino acid at position 3 of the glucagon antagonist may be glutamic acid, as opposed to the native glutamine residue of native glucagon.
  • the glucagon antagonist can comprise an amino acid sequence of:
  • the present invention also encompasses embodiments wherein the C-terminal amino acid of the glucagon antagonists have an amide group substituting for the carboxylic acid group that is present on the native amino acid.
  • the glucagon antagonists can be further modified to improve the peptide's solubility in aqueous solutions at physiological pH, while retaining the glucagon antagonist activity.
  • Introduction of hydrophilic groups at positions corresponding to positions 1, 16, 17, 20, 21, 24 and 29 of the native peptide, or at the C-terminus can improve the solubility of the resulting glucagon antagonist in solutions having a physiological pH, while retaining the parent compounds antagonist activity.
  • the presently disclosed glucagon antagonists are further modified to comprise one or more hydrophilic groups covalently linked to the side chains of amino acids corresponding to amino acid positions 1, 16, 17, 20, 21, 24 and 29 of the native glucagon peptide or of the N- or C-terminal amino acid.
  • the side chains of amino acids corresponding to amino acid positions 16 and 24 of the native glucagon peptide are covalently bound to hydrophilic groups, and in one embodiment the hydrophilic group is polyethylene glycol (PEG).
  • the glucagon antagonist comprises the shortened glucagon peptides, specifically 6-29 where the "N-terminal" amino acid is PLA (phenyl-lactic acid).
  • PLA phenyl-lactic acid
  • an amino acid of the glucagon antagonist is substituted with at least one cysteine residue, wherein the side chain of the cysteine residue is further modified with a thiol reactive reagent, including for example, maleimido, vinyl sulfone, 2-pyridylthio, haloalkyl, and haloacyl.
  • thiol reactive reagents may contain carboxy, keto, hydroxyl, and ether groups as well as other hydrophilic moieties such as polyethylene glycol units.
  • an amino acid of the glucagon antagonist is substituted with lysine, and the side chain of the substituting lysine residue is further modified using amine reactive reagents such as active esters (succinimido, anhydride, etc) of carboxylic acids or aldehydes of hydrophilic moieties such as polyethylene glycol.
  • amine reactive reagents such as active esters (succinimido, anhydride, etc) of carboxylic acids or aldehydes of hydrophilic moieties such as polyethylene glycol.
  • the lysine residue corresponding to position 12 of the native peptide is substituted with arginine and a single lysine substitution is inserted for one of the amino acids corresponding to position 1, 16, 17, 20, 21, 24 or 29 of the native peptide, or a lysine is added to the N- or C-terminus of the glucagon antagonist.
  • the methionine residue corresponding to position 27 of the native peptide is changed to leucine or norleucine to prevent oxidative degradation of the peptide.
  • the glucagon antagonists described herein are further modified by truncation or deletion of one or two amino acids of the C-terminus of the glucagon peptide (i.e., truncation of the amino acid at position 29 or at positions 28 and 29 of native glucagon) without affecting activity and/or potency at the glucagon receptor.
  • the glucagon antagonist described herein can, for example, consist essentially of or consist of amino acids 1-27, 1-28, 2-27, 2-28, 3-27, 3-28, 4-27, 4-28, 5-27, 5-28, 6-27, or 6-28 of the native glucagon peptide (SEQ ID NO: 1) with one or more modifications resulting in glucagon antagonistic activity as described herein.
  • the presently disclosed glucagon antagonists also encompass amino acid substitutions at positions that are known not to be critical to the function of the glucagon peptide.
  • the substitutions are conservative amino acid substitutions at one, two or three positions selected from the group consisting of 2, 5, 6, 7, 8, 9, 12, 13, 14, 15, 16, 19, 22, 23 or 24 of SEQ ID NO: 39.
  • the glucagon antagonist comprises a derivative peptide of SEQ ID NO: 42 wherein the glucagon peptide comprises a further amino acid substitution relative to SEQ ID NO: 42 at one to three amino acid positions selected from positions 2, 5, 6, 8, 9, 12, 13 and 14.
  • the substitutions at positions 2, 5, 6, 8, 9, 12, 13 and 14 of SEQ ID NO: 42 are conservative amino acid substitutions.
  • amino acids corresponding to positions 16, 17, 20, 21, 24 or 29 of the native peptide, and more particularly at position 21 and/or 24 are substituted with cysteine or lysine, wherein a PEG chain is covalently attached to the substituted cysteine or lysine residue.
  • the polyethylene chain may be in the form of a straight chain or it may be branched.
  • the polyethylene glycol chain has an average molecular weight selected from the range of about 500 to about 10,000 Daltons. In one embodiment the polyethylene glycol chain has an average molecular weight selected from the range of about 1,000 to about 5,000 Daltons. In one embodiment the polyethylene glycol chain has an average molecular weight selected from the range of about 1,000 to about 5,000 Daltons. In one embodiment the polyethylene glycol chain has an average molecular weight selected of about 1,000 to about 2,000 Daltons. In one embodiment the polyethylene glycol chain has an average molecular weight of about 1,000 Daltons.
  • the modified glucagon antagonist comprises two or more polyethylene chains covalently bound to the peptide wherein the total molecular weight of the glucagon chains is about 1,000 to about 5,000 Daltons.
  • the pegylated glucagon antagonist comprises a peptide selected from the group consisting of SEQ ID NO: 12, and SEQ ID NO: 22, wherein said peptide comprise a polyethylene glycol chain linked to the amino acid at positions 11 and 19 and the combined molecular weight of the two PEG chains is about 1,000 to about 5,000 Daltons.
  • the peptide comprises the sequence of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11, wherein R 1 is OH and R 2 is CONH 2 .
  • the peptide comprises the sequence of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11, wherein R 1 is OH, R 2 is CONH 2 and the amino acid at position 4 is aspartic acid, and in a further embodiment such peptides comprise a carboxy terminal extension comprising the sequence of SEQ ID NO: 19.
  • the peptide comprises a sequence selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 16, wherein the peptide is pegylated at position 11 for SEQ ID NO: 9 and SEQ ID NO: 13, pegylated at position 16 for SEQ ID NO: 10, and pegylated at position 19 for SEQ ID NO: 10 and SEQ ID NO: 14.
  • the glucagon agonist comprises the peptide of SEQ ID NO: 13 or SEQ ID NO: 14.
  • the C-terminal amino acid of the glucagon antagonists disclosed herein have an amide group in place of the carboxylic acid group that is present on the native amino acid.
  • the glucagon antagonist comprises the sequence of SEQ ID NO: 18.
  • a glucagon antagonist wherein a plasma protein has been covalently linked to an amino acid side chain of the peptide to improve the solubility, stability and/or pharmacokinetics of the glucagon peptide.
  • serum albumin can be covalently bound to the glucagon antagonists presented herein.
  • the plasma protein is covalently bound to an amino acid corresponding to position 16, 17, 20, 21, 24 or 29 of the native glucagon peptide.
  • the plasmid protein is bound to an amino acid corresponding to position 16 or 24 of the native glucagon peptide
  • the glucagon antagonist comprises the sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 36 and SEQ ID NO: 39.
  • the glucagon. antagonist comprises a peptide selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.
  • a glucagon antagonist wherein a linear amino acid sequence representing the Fc portion of an immunoglobin molecule has been covalently linked to an amino acid side chain of a glucagon antagonist disclosed herein to improve the solubility, stability and/or pharmacokinetics of the glucagon peptide.
  • the amino acid sequence representing the Fc portion of an immunoglobin molecule can be covalently bound to position 11, 12, 15, 16, 19, 21 or 24 of the glucagon peptide of SEQ ID NO: 7, SEQ ID NO: 39, or a glucagon analog thereof.
  • the Fc peptide is covalently bound to position 11 or 19 of the glucagon antagonist of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 36.
  • the Fc portion is usually isolated from IgG, but the Fc peptide fragment from any immunoglobin should function equivalently.
  • the glucagon peptide is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7 SEQ ID NO: 8, and SEQ ID NO: 39, wherein the Fc portion is linked to the corresponding position of 16, 17, 20, 21, 24 or 29 of the native glucagon peptide.
  • the glucagon analog comprises a glucagon peptide selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, wherein the Fc peptide is bound to the side chain of the amino acid located at position 11, 16 or 19 of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, respectively, and at both positions 11 and 19 for SEQ ID NO: 12.
  • the present disclosure also encompasses other conjugates in which glucagon peptides of the invention are linked, optionally via covalent bonding and optionally via a linker, to a conjugate.
  • Linkage can be accomplished by covalent chemical bonds, physical forces such electrostatic, hydrogen, ionic, van der Waals, or hydrophobic or hydrophilic interactions.
  • a variety of non-covalent coupling systems may be used, including biotin-avidin, ligand/receptor, enzyme/substrate, nucleic acid/nucleic acid binding protein, lipid/lipid binding protein, cellular adhesion molecule partners; or any binding partners or fragments thereof which have affinity for each other.
  • conjugates include but are not limited to a heterologous peptide or polypeptide (including for example, a plasma protein), a targeting agent, an immunoglobulin or portion thereof (e.g. variable region, CDR, or Fc region), a diagnostic label such as a radioisotope, fluorophore or enzymatic label, a polymer including water soluble polymers, or other therapeutic or diagnostic agents.
  • a conjugate is provided comprising a glucagon peptide of the present invention and a plasma protein, wherein the plasma protein is selected form the group consisting of albumin, transferin, fibrinogen and glubulins.
  • the plasma protein moiety of the conjugate is albumin or transferin.
  • the linker comprises a chain of atoms from 1 to about 60, or 1 to 30 atoms or longer, 2 to 5 atoms, 2 to 10 atoms, 5 to 10 atoms, or 10 to 20 atoms long.
  • the chain atoms are all carbon atoms.
  • the chain atoms in the backbone of the linker are selected from the group consisting of C, O, N, and S. Chain atoms and linkers may be selected according to their expected solubility (hydrophilicity) so as to provide a more soluble conjugate.
  • the linker provides a functional group that is subject to cleavage by an enzyme or other catalyst or hydrolytic conditions found in the target tissue or organ or cell.
  • the length of the linker is long enough to reduce the potential for steric hindrance.
  • the linker is a covalent bond or a peptidyl bond and the conjugate is a polypeptide
  • the entire conjugate can be a fusion protein.
  • peptidyl linkers may be any length. Exemplary linkers are from about 1 to 50 amino acids in length, 5 to 50, 3 to 5, 5 to 10, 5 to 15, or 10 to 30 amino acids in length.
  • Such fusion proteins may alternatively be produced by recombinant genetic engineering methods known to one of ordinary skill in the art.
  • the Asp-Ser sequence at position 15-16 of native glucagon has been identified as a uniquely unstable dipeptide that leads to premature chemical cleavage of the native hormone in aqueous buffers. For example, when maintained at O.O1N HCl at 37 °C for 2 weeks, more than 50% of the native glucagon may be cleaved into fragments.
  • the two liberated cleavage peptides 1-15 and 16-29 are devoid of glucagon-like biological activity and thus represent a limitation on the aqueous pre-formulation of glucagon and its related analogs.
  • the selective chemical substitution of the Asp at position 15 of the native glucagon peptide with Glu has been observed to virtually eliminate chemical cleavage of the 15-16 peptide bond.
  • the glucagon antagonists of the present invention can be similarly modified to decrease their susceptibility to premature chemical cleavage in aqueous buffers.
  • the glucagon antagonists described herein can be further modified to enhance their stability in aqueous solutions by replacing the native aspartic amino acid, located at position 15 of the native glucagon peptide, with an amino acid selected from the group consisting of cysteic acid, glutamic acid, homoglutamic acid and homocysteic acid.
  • the aspartic acid residue at position 10 of the glucagon antagonist of SEQ ID NO: 39 can be substituted with an amino acid selected from the group consisting of cysteic acid, glutamic acid, homoglutamic acid and homocysteic acid, and in one embodiment the native aspartic acid at position 10 of SEQ ID NO: 39 is replaced with glutamic acid.
  • a glucagon antagonist having improved stability in aqueous solutions wherein the antagonist comprises a sequence selected from the group consisting of SEQ ID NO: 36, SEQ ID NO: 40 and SEQ ID NO: 42.
  • the glucagon antagonist is amidated.
  • increased stability by way of reduced degradation of the glucagon antagonist described herein may also be achieved by substitution of the serine at position 16 (according to the numbering of native glucagon) with glutamic acid, cysteic acid, homo-glutamic acid,or homo-cysteic acid.
  • the serine at position 16 (according to the native glucagon sequence numbering) is replaced with glutamic acid.
  • the glucagon antagonist comprising such a modification comprises a C-terminal carboxylate and is not amidated.
  • a glucagon antagonist comprising a glucagon peptide selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 36, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43 and SEQ ID NO: 44, further modified by one or more additional amino acid substitutions at positions corresponding to positions 11, 12, 15, 16, 19 and/or 24 of the native glucagon peptide, wherein the amino acid substitutions comprise a substitution with an amino acid having a side chain suitable for crosslinking with hydrophilic moieties, including for example, PEG.
  • the native glucagon peptide can be substituted with a naturally occurring amino acid or a synthetic (non-naturally occurring) amino acid.
  • Synthetic or non-naturally occurring amino acids refer to amino acids that do not naturally occur in vivo but which, nevertheless, can be incorporated into the peptide structures described herein.
  • a glucagon antagonist is provided wherein the peptide comprises the sequence of SEQ ID NO: 7, SEQ ID NO: 36, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43 and SEQ ID NO: 44, and further comprises a polyethylene chain bound to corresponding position 21 or 24 of the native glucagon peptide.
  • the C-terminus of the glucagon peptide is modified to replace the carboxylic acid group with an amide group.
  • native glucagon can be modified by introducing charge at its carboxy terminus to enhance the solubility of the peptide while retaining the agonist properties of the peptide.
  • the enhanced solubility allows for the preparation and storage of glucagon solutions at near neutral pH.
  • Formulating glucagon solutions at relatively neutral pHs e.g. pH of about 6.0 to about 8.0 improves the long term stability of the glucagon peptides.
  • glucagon antagonists disclosed herein can be similarly modified to enhance their solubility in aqueous solutions at relatively neutral pH (e.g. pH of about 6.0 to about 8.0) while retaining the antagonist properties of the parent protein.
  • one embodiment of the present invention is directed to a glucagon antagonist of SEQ ID NO: 39 that has been further modified relative to the native amino acids present at positions 6-29 of the wild type glucagon (SEQ ID NO: 1) to add charge to the peptide by the substitution of native non-charged amino acids with charged amino acids, or the addition of charged amino acids to the carboxy terminus.
  • one to three of the non-charged native amino acids of the glucagon antagonist of SEQ ID NO: 39 are replaced with a charged amino acid.
  • the charged amino acid is selected from the group consisting of lysine, arginine, histidine, aspartic acid and glutamic acid. More particularly, applicants have discovered that substituting the normally occurring amino acid at corresponding position 28 and/or 29 relative to native glucagon with charged amino acids, and/or the addition of one to two charged amino acids at the carboxy terminus of the glucagon peptide, enhances the solubility and stability of the glucagon peptides in aqueous solutions at physiologically relevant pHs (i.e., a pH of about 6.5 to about 7.5). Accordingly, such modifications of the glucagon antagonist disclosed herein are anticipated to have a similar effect on the solubility in aqueous solutions, particularly at a pH ranging from about 5.5 to about 8.0, while retaining the parent peptide's biological activity
  • the glucagon antagonist of SEQ ID NO: 39 is modified by the substitution of the native amino acid at corresponding position 28 and/or 29 relative to native glucagon with a negatively charged amino acid (e.g., aspartic acid or glutamic acid) and optionally the addition of a negatively charged amino acid (e.g., aspartic acid or glutamic acid) to the carboxy terminus of the peptide.
  • a negatively charged amino acid e.g., aspartic acid or glutamic acid
  • a negatively charged amino acid e.g., aspartic acid or glutamic acid
  • the native glucagon peptide of SEQ ID NO: 39 is modified by the substitution of the native amino acid at corresponding position 29 relative to native glucagon with a positively charged amino acid (e.g., lysine, arginine or histidine) and optionally the addition of one or two positively charged amino acid (e.g., lysine, arginine or histidine) on the carboxy terminus of the peptide.
  • a positively charged amino acid e.g., lysine, arginine or histidine
  • one or two positively charged amino acid e.g., lysine, arginine or histidine
  • a glucagon analog having improved solubility and stability comprising the amino acid sequence of SEQ ID NO: 41 with the proviso that at least one amino acids at position, 23, or 24 of SEQ ID NO: 41 is substituted with an acidic amino acid, and/or an additional acidic amino acid is added at the carboxy terminus of SEQ ID NO: 41.
  • the acidic amino acids are independently selected from the group consisting of Asp, Glu, cysteic acid and homocysteic acid.
  • a glucagon antagonist having improved solubility and stability comprising the amino acid sequence of SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43 or SEQ ID NO: 44, wherein at least one of the amino acids at positions 23 or 24 is substituted with a non-native amino acid residue (i.e. at least one amino acid present at position 23 or 24 of the analog is an acidic amino acid different from the amino acid present at the corresponding position in SEQ ID NO: 7).
  • a glucagon agonist comprising the sequence of SEQ ID NO: 41 or 42 with the proviso that when the amino acid at position 23 is asparagine and the amino acid at position 24 is threonine, the peptide further comprises one to two amino acids, independently selected from the group consisting of Lys, Arg, His, Asp or Glu, added to the carboxy terminus of the glucagon antagonist.
  • the present disclosure also encompasses glucagon antagonist fusion peptides wherein a second peptide has been fused to the c-terminus of the glucagon antagonist.
  • the fusion peptide may comprise a glucagon antagonist peptide of SEQ ID NO: 44 that further comprises an amino acid sequence of SEQ ID NO: 19 (GPSSGAPPPS), SEQ ID NO: 20 (Lys Arg Asn Arg Asn Asn Ile Ala) or SEQ ID NO: 21 (Lys Arg Asn Arg) linked to the c-terminal amino acid of the glucagon antagonist.
  • the amino acid sequence of SEQ ID NO: 19 is bound to amino acid 24 of the glucagon antagonist of SEQ ID NO: 42 through a peptide bond.
  • the fusion peptide comprises a glucagon antagonist peptide of SEQ ID NO: 7, SEQ ID NO: 36, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 43 that further comprises an amino acid sequence of SEQ ID NO: 19 (GPSSGAPPPS) linked to amino acid 24 of the glucagon antagonist.
  • the fusion peptide comprises a glucagon antagonist peptide of SEQ ID NO: 7, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 41 or SEQ ID NO: 43 that further comprises an amino acid sequence of SEQ ID NO: 20, SEQ ID NO: 21 or SEQ ID NO: 53 linked to amino acid 24 of the glucagon antagonist.
  • the glucagon antagonist fusion peptide comprises a sequence selected from the group consisting of SEQ ID NO: 46 and SEQ ID NO 47.
  • the C-terminus of the fusion peptide is modified to replace the carboxylic acid group with an amide group.
  • a glucagon antagonist fusion peptide wherein the glucagon antagonist portion of the fusion peptide is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 10, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 39 and the sequence of SEQ ID NO: 19 is fused to the carboxy terminus of the glucagon antagonist portion, and wherein the PEG chain, when present, is selected from the range of 500 to 40,000 Daltons.
  • the glucagon antagonist segment is selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 46 and SEQ ID NO: 47 wherein the PEG chain is selected from the range of about 500 to about 5,000 Daltons, and more particularly, in one .embodiment the PEG chain is about 1,000 Daltons.
  • the C-terminus is modified to replace the carboxylic acid group with an amide group.
  • the glucagon antagonist may further comprise one to two charged amino acids added to the carboxy terminus.
  • the amino acids are negatively charged amino acids, including for example glutamic acid and aspartic acid.
  • the glucagon antagonist comprises the sequence of SEQ ID NO: 42 wherein at least one of corresponding positions 27 and 28 relative to the native glucagon peptide comprises an amino acid selected from the group consisting of aspartic acid and glutamic acid and wherein SEQ ID NO: 42 is optionally modified to include an addition one to two negatively charged amino acids added to the carboxy terminus.
  • the negatively charged amino acids are glutamic acid or aspartic acid.
  • the solubility of the glucagon antagonist of SEQ ID NO: 42 can be improved by covalently linking a hydrophilic moiety to an amino acid residue at position 11, 12, 15, 16, 19 or 24, and in one embodiment the hydrophilic moiety is linked to an amino acid at position 11, 16 or 19, and in a further embodiment the hydrophilic moiety is linked to amino acid 19.
  • the hydrophilic moiety is a plasma protein or the Fc portion of an immunoglobin, and in an alternative embodiment the hydrophilic moiety is a hydrophilic hydrocarbon chain.
  • the hydrophilic moiety is polyethylene glycol, having a molecular weight selected from the range of about 1,000 to about 5,000 Daltons.
  • the hydrophilic moiety is polyethylene glycol, having a molecular weight of at least about 20,000 Daltons.
  • the polyethylene modified glucagon antagonist comprises the amino acids sequence of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ NO: 12, SEQ ID NO: 43, SEQ ID NO: 44 or SEQ ID NO: 45.
  • the glucagon antagonist comprises the general structure of A-B-C, wherein
  • the glucagon antagonist comprises an oxy derivative of PLA, e.g., an ester of PLA or an ether of PLA.
  • the ester of PLA comprises the structure of Formula IV: wherein R7 is an ester formed upon reaction of the hydroxyl of PLA with a carbonyl bearing a nucleophile.
  • the oxy derivative of PLA comprises a chemical moiety selected from the group consisting of a polymer (e.g., a polyalkylene glycol), a carbohydrate, an amino acid, a peptide, and a lipid, e.g., a fatty acid or a steroid, wherein the chemical moiety is linked to PLA via an oxygen-containing bond (e.g., an ester or ether bond).
  • a polymer e.g., a polyalkylene glycol
  • carbohydrate e.g., an amino acid, a peptide
  • a lipid e.g., a fatty acid or a steroid
  • the chemical moiety is an amino acid, which, optionally, is a part of a peptide, such that Formula IV is a depsipeptide.
  • PLA may be at a position other than the N-terminal amino acid residue of the glucagon antagonist, such that the glucagon antagonist comprises one or more (e.g., 1, 2, 3, 4, 5, 6, or more) amino acids N-terminal to the PLA residue.
  • the glucagon antagonist can comprise PLA at position n, wherein n is 2, 3, 4, 5, or 6 of the glucagon antagonist.
  • the amino acids N-terminal to the PLA residue may be synthetic or naturally-occurring.
  • the amino acids which are N-terminal to PLA are naturally-occurring amino acids.
  • the amino acids which are N-terminal to PLA are the N-terminal amino acids of native glucagon.
  • the glucagon antagonist can comprise at the N-terminus the amino acid sequence of any of SEQ ID NOs: 54-58, wherein PLA is linked to threonine via an ester bond:
  • one or more of the N-terminal amino acids may be substituted with an amino acid other than the amino acid of native glucagon.
  • the glucagon antagonist comprises PLA as the amino acid at position 5 or 6
  • the amino acid at position 1 and/or position 2 may be an amino acid which reduces susceptibility to cleavage by dipeptidyl peptidase IV.
  • position 1 of the glucagon antagonist is an amino acid selected from the group consisting of D-histidine, alpha, alpha-dimethyl imidiazole acetic acid (DMIA), N-methyl histidine, alpha-methyl histidine, imidazole acetic acid, desaminohistidine, hydroxyl-histidine, acetyl-histidine and homo-histidine.
  • position 2 of the antagonist peptide is an amino acid selected from the group consisting of D-serine, D-alanine, valine, glycine, N-methyl serine, N-methyl alanine, and aminoisobutyric acid (AIB).
  • the polymer may be any polymer, provided that it can react with the hydroxyl of PLA.
  • the polymer may be one that naturally or normally comprises a carbonyl with nucleophile, for example.
  • the polymer may be one which was derivatized to comprise the carbonyl bearing a nucleophile.
  • the polymer may be a derivatized polymer of any of: polyamides, polycarbonates, polyalkylenes and derivatives thereof including, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polymers of acrylic and methacrylic esters, including poly(methyl methacrylate), poly(ethyl methacrylate), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate), polyvinyl polymers including polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, poly(vinyl acetate), and polyvinyl
  • the polymer can be a biodegradable polymer, including a synthetic biodegradable polymer (e.g., polymers of lactic acid and glycolic acid, polyanhydrides, poly(ortho)esters, polyurethanes, poly(butic acid), poly(valeric acid), and poly(lactide-cocaprolactone)), and a natural biodegradable polymer (e.g., alginate and other polysaccharides including dextran and cellulose, collagen, chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), albumin and other hydrophilic proteins (e.g., zein and other prolamines and hydrophobic proteins)), as well as any copolymer or mixture thereof.
  • these materials degrade either by enzymatic hydrolysis or exposure to water in vivo, by surface or bulk erosion.
  • the polymer is a water-soluble polymer.
  • Suitable water-soluble polymers include, for example, polyvinylpyrrolidone, hydroxypropyl cellulose (HPC; Klucel), hydroxypropyl methylcellulose (HPMC; Methocel), nitrocellulose, hydroxypropyl ethylcellulose, hydroxypropyl butylcellulose, hydroxypropyl pentylcellulose, methyl cellulose, ethylcellulose (Ethocel), hydroxyethyl cellulose, various alkyl celluloses and hydroxyalkyl celluloses, various cellulose ethers, cellulose acetate, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, vinyl acetate/crotonic acid copolymers, poly-hydroxyalkyl methacrylate, hydroxymethyl methacrylate, methacrylic acid copolymers, polymethacrylic acid, polymethylmethacrylate, maleic anhydride/methyl vinyl ether
  • the polymer is a polyalkylene glycol, including, for example, polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • the carbohydrate may be any carbohydrate provided that it comprises or is made to comprise a carbonyl with an alpha leaving group.
  • the carbohydrate for example, may be one which has been derivatized to comprise a carbonyl with an alpha leaving group.
  • the carbohydrate may be a derivatized form of a monosaccharide (e.g., glucose, galactose, fructose), a disaccharide (e.g., sucrose, lactose, maltose), an oligosaccharide (e.g., raffinose, stachyose), a polysaccharide (a starch, amylase, amylopectin, cellulose, chitin, callose, laminarin, xylan, mannan, fucoidan, galactomannan.
  • a monosaccharide e.g., glucose, galactose, fructose
  • a disaccharide
  • the lipid may be any lipid comprising a carbonyl with an alpha leaving group.
  • the lipid for example, may be one which is derivatized to comprise the carbonyl.
  • the lipid may be a derivative of a fatty acid (e.g., a C4-C30 fatty acid, eicosanoid, prostaglandin, leukotriene, thromboxane, N-acyl ethanolamine), glycerolipid (e.g., mono-, di-, trisubstituted glycerols), glycerophospholipid (e.g., phosphatidylcholine, phosphatidylinositol, phosphatidylethanolamine, phosphatidylserine), sphingolipid (e.g., sphingosine, ceramide), sterol lipid (e.g., steroid, cholesterol), prenol lipid, saccharolipid, or a polyketide. oil, wax, cholesterol, sterol, fat-soluble vitamin, monoglyceride, diglyceride, triglyceride, a phospholipid.
  • a fatty acid
  • R7 has a molecular weight of about 40 kDa or less. Accordingly, R7 has a molecular weight of about 35 kDa or less, about 30 kDa or less, about 25 kDa or less, about 20 kDa or less, about 15 kDa or less, about 10 kDa or less, about 5 kDa or less, or about 1 kDa.
  • the glucagon antagonist comprises as A a peptide of 2 to 6 amino acids in which two consecutive amino acids of the peptide are linked via an ester or ether bond.
  • the peptide may comprise any amino acids, synthetic or naturally occurring, provided that at least two consecutive amino acids of the peptide are linked via an ester or ether bond.
  • the peptide of A comprises amino acids of native glucagon.
  • the peptide can comprise j to 6 of native glucagon (SEQ ID NO: 1), wherein j is 1, 2, 3, 4, or 5.
  • the peptide can comprise an amino acid sequence based on the N-terminus of SEQ ID NO:1 with one or more amino acid modifications.
  • the peptide can comprise at position 1 of the glucagon antagonist an amino acid selected from the group consisting of D-histidine, alpha, alpha-dimethyl imidiazole acetic acid (DMIA), N-methyl histidine, alpha-methyl histidine, imidazole acetic acid, desaminohistidine, hydroxyl-histidine, acetyl-histidine and homo-histidine.
  • position 2 of the antagonist peptide is an amino acid selected from the group consisting of D-serine, D-alanine, valine, glycine, N-methyl serine, N-methyl alanine, and aminoisobutyric acid (AIB).
  • the amino acid at position 3 of the glucagon antagonist may be glutamic acid, as opposed to the native glutamine residue of native glucagon.
  • the glucagon antagonist can comprise an amino acid sequence of:
  • B represents amino acids of native glucagon, e.g., i to 26 of SEQ ID NO: 1, wherein i is 3, 4, 5, 6, or 7, optionally comprising one or more amino acid modifications.
  • B represents amino acids 7 to 26 of SEQ ID NO: 1, optionally further modified.
  • B is modified by up to three amino acid modifications.
  • B which represents native amino acid sequence of SEQ ID NO: 1 is modified by one or more conservative amino acid modifications.
  • the glucagon antagonist comprises one or more charged amino acids at the C-terminus.
  • Y and/or Z can be a charged amino acid, e.g., Lys, Arg, His, Asp, and Glu.
  • the glucagon antagonist comprises one to two charged amino acids (e.g., Lys, Arg, His, Asp, and Glu) C-terminal to Z.
  • Z followed by one to two charged amino acids does not comprise R10.
  • the glucagon antagonist in one embodiment comprises a hydrophilic moiety covalently bound to an amino acid residue of the glucagon antagonist, as described herein.
  • the glucagon antagonist can comprise a hydrophilic moiety covalently attached to an amino acid at position 1, 16, 20, 21, or 24 according to the numbering of SEQ ID NO: 1.
  • the hydrophilic moiety is attached to the C-terminal amino acid of the glucagon antagonist, which in some cases, is 1 or 11 amino acids C-terminal to Z.
  • the hydrophilic moiety is attached to PLA, when A is PLA, PLA-Phe, or PLA-Thr-Phe, wherein PLA is modified to comprise the hydrophilic moiety.
  • an amino acid comprising a hydrophilic moiety is added to the N- or C-terminus of the glucagon antagonist.
  • the glucagon antagonist comprises an acyl group or alkyl group as described herein.
  • the acylation or alkylation can occur off the side chain of the amino acid at position 10, 20, or 24, according to the numbering of SEQ ID NO: 1.
  • the acylation or alkylation occurs off the side chain of the C-terminal amino acid of the glucagon antagonist, which in some cases, is 1 or 11 amino acids C-terminal to Z.
  • A is PLA, PLA-Phe, or PLA-Thr-Phe
  • the PLA is modified to comprise an acyl or alkyl group.
  • the glucagon antagonist comprises the amino acid sequence of any of SEQ ID NOs: 62, 64-67, and 71.
  • the disclosed glucagon antagonists are believed to be suitable for any use that has previously been described for other glucagon antagonists. Accordingly, the modified glucagon peptides described herein can be used to treat hyperglycemia, or treat other metabolic diseases that result from high blood levels of glucagon or high blood glucose levels.
  • the patient to be treated using the glucagon antagonists disclosed herein is a domesticated animal, and in another embodiment the patient to be treated is a human. Studies suggest that lack of glucagon suppression in diabetic patients contributes to postprandial hyperglycemia in part via accelerated glycogenolysis.
  • the glucagon antagonist of the present invention can be used to treat hyperglycemia, and are expected to be useful for treating a variety of types of diabetes including diabetes mellitus type I, diabetes mellitus type II, or gestational diabetes, either insulin-dependent or non-insulin-dependent, and reducing complications of diabetes including nephropathy, retinopathy and vascular disease.
  • Exendin-4 is a peptide made up of 39 amino acids. It is a powerful stimulator of a receptor known as GLP-1. This peptide has also been reported to suppress appetite and induce weight loss. Applicants have found that the terminal sequence of Exendin-4 when added at the carboxy terminus of glucagon improves the solubility and stability of glucagon without compromising the bioactivity of glucagon.
  • the glucagon antagonist disclosed herein are administered to patients as a method of reducing appetite or promoting loss of body weight.
  • the patient is a domesticated animal, and in another embodiment the patient to be treated is a human.
  • the terminal ten amino acids of Exendin-4 i.e.
  • the sequence of SEQ ID NO: 19 (GPSSGAPPPS)) are linked to the carboxy terminus of a glucagon antagonists disclosed herein. These fusion proteins are anticipated to have pharmacological activity for suppressing appetite and inducing weight loss/weight maintenance.
  • the glucagon antagonists disclosed herein can be further modified to include the amino acid sequence of SEQ ID NO: 19 (GPSSGAPPPS) linked to amino acid 24 of the glucagon antagonist of SEQ ID NO: 42 and administered to individuals to induce weight loss or assist in weight maintenance.
  • the glucagon peptide comprises a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO: 3, SEQ ID NO: 4 SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO:7, (SEQ ID NO: 8, SEQ ID NO: 36, SEQ ID NO: 39, SEQ ID NO: 40 SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43 and SEQ ID NO: 44 and further comprising the amino acid sequence of SEQ ID NO: 19 (GPSSGAPPPS) linked to amino acid 24 of the glucagon antagonist is used to suppress appetite and inducing weight loss/weight maintenance.
  • the administered glucagon antagonist comprises the sequence of SEQ ID NO: 46 or SEQ ID NO: 47.
  • Such methods for reducing appetite or promoting loss of body weight are expected to be useful in reducing body weight, preventing weight gain, or treating obesity of various causes, including drug-induced obesity, and reducing complications associated with obesity including vascular disease (coronary artery disease, stroke, peripheral vascular disease, ischemia reperfusion, etc.), hypertension, onset of diabetes type II, hyperlipidemia and musculoskeletal diseases.
  • vascular disease coronary artery disease, stroke, peripheral vascular disease, ischemia reperfusion, etc.
  • hypertension onset of diabetes type II
  • hyperlipidemia hyperlipidemia and musculoskeletal diseases.
  • the glucagon peptides of the invention may be administered alone or in combination with other anti-diabetic or anti-obesity agents.
  • Anti-diabetic agents known in the art or under investigation include insulin, sulfonylureas, such as tolbutamide (Orinase), acetohexainide (Dymelor), tolazamide (Tolinase), chlorpropamide (Diabinese), glipizide (Glucotrol), glyburide (Diabeta, Micronase, Glynase), glimepiride (Amaryl), or gliclazide (Diamicron); meglitinides, such as repaglinide (Prandin) or nateglinide (Starlix); biguanides such as metformin (Glucophage) or phenformin; thiazolidinediones such as rosiglitazone (Avandia), pioglitazone (Actos
  • Anti-obesity agents known in the art or under investigation include appetite suppressants, including phenethylamine type stimulants, phentermine (optionally with fenfluramine or dexfenfluramine), diethylpropion (Tenuate®), phendimetrazine (Prelu-2®, Bontril®), benzphetamine (Didrex®), sibutramine (Meridia®, Reductil®); rimonabant (Acomplia®), other cannabinoid receptor antagonists; oxyntomodulin; fluoxetine hydrochloride (Prozac); Qnexa (topiramate and phentermine), Excalia (bupropion and zonisamide) or Contrave (bupropion and naltrexone); or lipase inhibitors, similar to xenical (Orlistat) or Cetilistat (also known as ATL-962), or GT 389-255.
  • appetite suppressants including phenethylamine type stimulants
  • the glucagon antagonists of the present invention can also be administered to patients suffering from catabolic wasting. It is estimated that over half of cancer patients experience catabolic wasting which is characterized by unintended and progressive weight loss, weakness, and low body fat and muscle. The syndrome is equally common in AIDS patients and can also be present in bacterial and parasitic diseases, rheumatoid arthritis, and chronic diseases of the bowel, liver, lungs, and heart. It is usually associated with anorexia and can manifest as a condition in aging or as a result of physical trauma. Catabolic wasting is a symptom that diminishes the quality of life, worsens the underlying condition, and is a major cause of death. Applicants anticipate that the glucagon antagonists disclosed herein can be administered to patients to treat catabolic wasting.
  • compositions comprising the glucagon antagonists disclosed herein can be formulated and administered to patients to using standard pharmaeuctically acceptable carriers and routes of administration known to those skilled in the art. Accordingly the present disclosure also encompasses pharmaceutical compositions comprising one or more of the glucagon antagonists disclosed herein in combination with a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions may comprise the glucagon antagonists as the sole pharmaceutically active component, or the glucagon antagonists can be combined with one or more additional active agents.
  • a composition is provided comprising a glucagon antagonist of the present invention and a compound that activates the GLP-1 receptor (such as GLP-1, a GLP-1 analog, an exendin-4 analog, or derivatives thereof).
  • a composition comprising a glucagon antagonist of the present invention and insulin or an insulin analog.
  • a composition provided for inducing weight loss or preventing weight gain can be provided that comprises the sequence of SEQ ID NO: 42 further comprising the amino acid sequence of SEQ ID NO: 19 (GPSSGAPPPS) linked to amino acid 24 of SEQ ID NO: 42, and an anti-obesity peptide.
  • Suitable anti-obesity peptides include those disclosed in US patents 5,691,309 , 6,436,435 or US Patent application 20050176643 , and including, but limited to GLP-1, GIP (Gastric Inhibitory Polypeptide), MP1, PYY, MC-4, Leptin.
  • a pharmaceutical composition comprising any of the novel glucagon peptides disclosed herein, preferably sterile and preferably at a purity level of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, and a pharmaceutically acceptable diluent, carrier or excipient.
  • compositions may contain a glucagon peptide at a concentration of at least 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 6 mg/ml, 7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 11 mg/ml, 12 mg/ml, 13 mg/ml, 14 mg/ml, 15 mg/ml, 16 mg/ml, 17 mg/ml, 18 mg/ml, 19 mg/ml, 20 mg/ml, 21 mg/ml, 22 mg/ml, 23 mg/ml, 24 mg/ml, 25 mg/ml or higher.
  • the pharmaceutical compositions comprise aqueous solutions that are sterilized and optionally stored within various containers.
  • the compounds of the present invention can be used in accordance with one embodiment to prepare pre-formulated solutions ready for injection.
  • the pharmaceutical compositions comprise a lyophilized powder.
  • the pharmaceutical compositions can be further packaged as part of a kit that includes a disposable device for administering the composition to a patient.
  • the containers or kits may be labeled for storage at ambient room temperature or at refrigerated temperature.
  • glucagon antagonist includes all pharmaceutically acceptable salts thereof.
  • Pegylating glucagon antagonists can improve the aqueous solubility of the antagonists. However, increasing the length of the PEG chain, or attaching multiple PEG chains to the peptide, such that the total molecular weight of the linked PEG is greater than 5,000 Daltons, begins to delay the time action of the modified glucagon antagonist.
  • a glucagon antagonist is provided wherein the peptide comprises one or more polyethylene glycol chains, wherein the total molecular weight of the linked PEG is greater than 5,000 Daltons, and in one embodiment is greater than 10,000 Daltons.
  • modified glucagon antagonists have a delayed time of activity but without loss of bioactivity. Accordingly, such compounds can be administered prophylactically to extend the effect of the administered glucagon antagonist.
  • the pegylated glucagon antagonist comprises a peptide selected from the group consisting of (SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, (SEQ ID NO: 12, SEQ ID NO: 43, SEQ ID NO: 44 and SEQ ID NO: 45, wherein the side chain of an amino acid residue at position 11, 16 or 19 of the peptide is covalently bound to one or more polyethylene glycol chains, wherein the total molecular weight of the PEG chain(s) is greater than about 10,000 Daltons. In one embodiment the molecular weight of the PEG chain(s) is greater than 10,000 and less than or equal to 40,000 Daltons.
  • the pegylated glucagon antagonist comprises the peptide of SEQ ID NO: 9 or SEQ ID NO: 43, wherein an amino acid residue at position 11 of the peptide is covalently linked to a polyethylene glycol chain having a molecular weight selected from the range of about 10,000 to about 40,000 Daltons.
  • the pegylated glucagon antagonist comprises the peptide of SEQ ID NO: 10 or SEQ ID NO: 44, wherein an amino acid residue at position 16 of the peptide is covalently linked to a polyethylene glycol chain having a molecular weight selected from the range of about 10,000 to about 40,000 Daltons.
  • the pegylated glucagon antagonist comprises the peptide of SEQ ID NO: 11 or SEQ ID NO: 45, wherein an amino acid residue at position 19 of the peptide is covalently linked to a polyethylene glycol chain having a molecular weight selected from the range of about 10,000 to about 40,000 Daltons.
  • the pegylated glucagon antagonist comprises the peptide of SEQ ID NO: 13, SEQ ID NO. 14, SEQ ID NO: 15 or SEQ ID NO: 16 wherein the covalently linked PEG chain has a molecular weight of at least about 10,000 Daltons, and in one embodiment the molecular weight of the PEG is selected from the range of about 20,000 to about 40,000 Daltons.
  • the pegylated glucagon agonist comprises the peptide of SEQ ID NO: 12, SEQ ID NO: 17 or SEQ ID NO: 22, wherein a PEG chain is covalently linked to the amino acid residue at position 11 and at position 19, wherein the combined molecular weight of the two PEG chains is at least about 10,000 Daltons.
  • glucagon antagonists disclosed herein can be combined with other active agents, including for example, insulin, to treat diseases or conditions that are characterized by excessive glucagon activity.
  • glucagon antagonists that have been modified to be covalently bound to a PEG chain having a molecular weight of greater than 10,000 Daltons can be administered in conjunction with insulin to help to maintain stable blood glucose levels in diabetics.
  • the glucagon antagonists of the present disclosure can be co-administered with insulin as a single composition, simultaneously administered as separate solutions, or alternatively, the insulin and the glucagon antagonist can be administered at different times relative to one another.
  • the composition comprising insulin and the composition comprising the glucagon antagonist are administered within 12 hours of one another. The exact ratio of the glucagon antagonist relative to the administered insulin will be dependent in part on determining the glucagon levels of the patient, and can be determined through routine experimentation.
  • the present disclosure also encompasses multimers of the modified glucagon antagonists disclosed herein.
  • Two or more of the modified glucagon peptides can be linked together using standard linking agents and procedures known to those skilled in the art.
  • dimers can be formed between two modified glucagon antagonists through the use of bifunctional thiol crosslinkers and bi-functional amine crosslinkers, particularly for glucagon antagonists that have been substituted (at positions 11, 16 or 19, for example) with cysteine, lysine ornithine, homocysteine or acetyl phenylalanine residues (e.g. SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12).
  • the dimer can be a homodimer or alternatively can be a heterodimer.
  • the dimer is formed between two glucagon antagonists independently selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 45, SEQ ID NO: 46, or SEQ ID NO: 47, wherein the two peptides are linked to one another via a linker attached to position 11 of each peptide, 16 of each peptide, or position 19 of each peptide or any combination thereof.
  • the linkage is a disulfide linkage between a Cys11 to Cys11 or a Cys19 to Cys19 or a Cys11 to Cys19 residue of the respective glucagon antagonist peptides.
  • a dimer can be formed between two glucagon antagonist peptides independently selected form the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 42 wherein the linkage is formed between amino acid positions independently selected from positions 16, 21 and 24 with respect to the native glucagon peptide.
  • a glucagon antagonist dimer comprising two glucagon antagonists, each comprising the sequence of SEQ ID NO: 46, wherein the two antagonists are linked to one another by a disulfide bond through amino acid position 25.
  • a glucagon antagonist dimer is provided comprising two glucagon antagonists, each comprising the sequence of SEQ ID NO: 47, wherein the two antagonists are linked to one another by a disulfide bond through amino acid position 35.
  • the dimer is formed from glucagon antagonists of SEQ ID NO: 46 and SEQ ID NO: 47 wherein the amino acid at position 10 is glutamic acid.
  • the dimer comprises a homodimer of a glucagon antagonist fusion peptide selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 36, SEQ ID NO: 37, SEQID NO: 40, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42 and pharmaceutically acceptable salts of said glucagon antagonists.
  • a dimer comprising a first glucagon antagonist bound to a second glucagon antagonist via a linker, wherein the first and second glucagon peptides of the dimer are independently selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41,, and SEQ ID NO: 42, and pharmaceutically acceptable salts of said glucagon polypeptides.
  • the first and second glucagon peptides of the dimer are independently selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 36 and SEQ ID NO: 39.
  • the dimer comprises a homodimer of a glucagon antagonist selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31.
  • a glucagon antagonist dimer is provided wherein the first and second glucagon peptides of the dimer comprise an amino acid sequence independently selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28.
  • the dimer comprises a homodimer of a glucagon antagonist selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 11 and SEQ ID NO: 12, wherein the glucagon peptide further comprises a polyethylene glycol chain covalently bound to position 11 or 19 of the glucagon peptide.
  • the modified glucagon peptides of the present invention can be provided in accordance with one embodiment as part of a kit.
  • a kit for administering a glucagon agonist to a patient in need thereof is provided wherein the kit comprises a modified glucagon antagonist selected from the group consisting of
  • the kit is provided with a device for administering the glucagon antagonist composition to a patient
  • the kit may further include a variety of containers, e.g., vials, tubes, bottles, and the like.
  • the kits will also include instructions for use.
  • the device of the kit is an aerosol dispensing device, wherein the composition is prepackaged within the aerosol device.
  • the kit comprises a syringe and a needle, and in one embodiment the glucagon antagonist composition is prepackaged within the syringe.
  • a glucagon antagonist comprising (either by amino acid substitution or insertion) one or more ⁇ , ⁇ -disubstituted amino acids at the C-terminal portion of the glucagon peptide (around amino acids 12-29 according to the amino acid numbering of wild type glucagon).
  • the ⁇ , ⁇ -disubstituted amino acid is one of amino iso-butyric acid (AIB), an amino acid disubstituted with the same or a different group selected from methyl, ethyl, propyl, and n-butyl, or with a cyclooctane or cycloheptane (e.g., 1-aminocyclooctane-1-carboxylic acid).
  • AIB amino iso-butyric acid
  • an amino acid disubstituted with the same or a different group selected from methyl, ethyl, propyl, and n-butyl or with a cyclooctane or cycloheptane (e.g., 1-aminocyclooctane-1-carboxylic acid).
  • a cyclooctane or cycloheptane e.g., 1-aminocyclooctane-1-car
  • one, two, three or all of positions 16, 20, 21, and 24 are substituted with AIB.
  • the glucagon antagonist comprises one or more ⁇ , ⁇ -disubstituted amino acids, e.g., AIB
  • the glucagon antagonist comprises a C-terminal carboxylate and is not amidated at the C-terminus.
  • the solubility of the glucagon antagonists disclosed herein are enhanced by the covalent linkage of a hydrophilic moiety to the peptide.
  • Hydrophilic moieties can be attached to the glucagon antagonists under any suitable conditions used to react a protein with an activated polymer molecule.
  • Any means known in the art can be used, including via acylation, reductive alkylation, Michael addition, thiol alkylation or other chemoselective conjugation/ligation methods through a reactive group on the PEG moiety (e.g., an aldehyde, amino, ester, thiol, ⁇ -haloacetyl, maleimido or hydrazino group) to a reactive group on the target compound (e.g., an aldehyde, amino, ester, thiol, ⁇ -haloacetyl, maleimido or hydrazino group).
  • a reactive group on the PEG moiety e.g., an aldehyde, amino, ester, thiol, ⁇ -haloacetyl, maleimido or hydrazino group
  • a reactive group on the target compound e.g., an aldehyde, amino, ester, thiol, ⁇ -haloacety
  • Activating groups which can be used to link the water soluble polymer to one or more proteins include without limitation sulfone, maleimide, sulfhydryl, thiol, triflate, tresylate, azidirine, oxirane and 5-pyridyl. If attached to the antagonist peptide by reductive alkylation, the polymer selected should have a single reactive aldehyde so that the degree of polymerization is controlled. See, for example, Kinstler et al., Adv. Drug. Delivery Rev. 54: 477-485 (2002 ); Roberts et al., Adv. Drug Delivery Rev. 54: 459-476 (2002 ); and Zalipsky et al., Adv. Drug Delivery Rev. 16: 157-182 (1995 ).
  • Suitable hydrophilic moieties include polyethylene glycol (PEG), polypropylene glycol, polyoxyethylated polyols (e.g., POG), polyoxyethylated sorbitol, polyoxyethylated glucose, polyoxyethylated glycerol (POG), polyoxyalkylenes, polyethylene glycol propionaldehyde, copolymers of ethylene glycol/propylene glycol, monomethoxy-polyethylene glycol, mono-(C1-C10) alkoxy- or aryloxy-polyethylene glycol, carboxymethylcellulose, polyacetals, polyvinyl alcohol (PVA), polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, poly (.beta.-amino acids) (either homopolymers or random copolymers), poly(n-vinyl pyrrol
  • the hydrophilic moiety e.g., polyethylene glycol chain in accordance with some embodiments has a molecular weight selected from the range of about 500 to about 40,000 Daltons.
  • the hydrophilic moiety, e.g. PEG has a molecular weight selected from the range of about 500 to about 5,000 Daltons, or about 1,000 to about 5,000 Daltons.
  • the hydrophilic moiety, e.g., PEG has a molecular weight of about 10,000 to about 20,000 Daltons.
  • the hydrophilic moiety, e.g., PEG has a molecular weight of about 20,000 to about 40,000 Daltons.
  • dextrans are used as the hydrophilic moiety.
  • Dextrans are polysaccharide polymers of glucose subunits, predominantly linked by ⁇ 1-6 linkages. Dextran is available in many molecular weight ranges, e.g., about 1 kD to about 100 kD, or from about 5, 10, 15 or 20 kD to about 20, 30, 40, 50, 60, 70, 80 or 90 kD.
  • Linear or branched polymers are contemplated.
  • Resulting preparations of conjugates may be essentially monodisperse or polydisperse, and may have about 0.5, 0.7, 1, 1.2, 1.5 or 2 polymer moieties per antagonist peptide.
  • the hydrophilic moiety is a polyethylene glycol (PEG) chain, optionally linked to the antagonist at one or more of positions 1, 16, 17, 21, 24, 29 (according to the amino acid numbering of wild type glucagon), a position within a C-terminal extension, e.g., 30, or at the N- or C-terminal amino acid.
  • the native amino acid at that position is substituted with an amino acid having a side chain suitable for crosslinking with hydrophilic moieties, to facilitate linkage of the hydrophilic moiety to the antagonist.
  • the native amino acid at that position is substituted with Lys, Cys, Orn, homocysteine, or acetyl-phenylalanine residue.
  • an amino acid modified to comprise a hydrophilic group is added to the peptide at the N- or C-terminus.
  • the present disclosure also encompasses other conjugates in which glucagon antagonists of the invention are linked, optionally via covalent bonding and optionally via a linker, to a conjugate moiety.
  • Linkage can be accomplished by covalent chemical bonds, physical forces such electrostatic, hydrogen, ionic, van der Waals, or hydrophobic or hydrophilic interactions.
  • a variety of non-covalent coupling systems may be used, including biotin-avidin, ligand/receptor, enzyme/substrate, nucleic acid/nucleic acid binding protein, lipid/lipid binding protein, cellular adhesion molecule partners; or any binding partners or fragments thereof which have affinity for each other.
  • the antagonist can be linked to conjugate moieties via direct covalent linkage by reacting targeted amino acid residues of the antagonist with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of these targeted amino acids.
  • Reactive groups on the antagonist or conjugate include, e.g., an aldehyde, amino, ester, thiol, ⁇ -haloacetyl, maleimido or hydrazino group.
  • Derivatizing agents include, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride or other agents known in the art.
  • the conjugate moieties can be linked to the antagonist indirectly through intermediate carriers, such as polysaccharide or polypeptide carriers. Examples of polysaccharide carriers include aminodextran.
  • suitable polypeptide carriers include polylysine, polyglutamic acid, polyaspartic acid, co-polymers thereof, and mixed polymers of these amino acids and others, e.g., serines, to confer desirable solubility properties on the resultant loaded carrier.
  • Cysteinyl residues most commonly are reacted with ⁇ -haloacetates (and corresponding amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Cysteinyl residues also are derivatized by reaction with bromotrifluoroacetone, alpha-bromo- ⁇ -(5-imidozoyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.
  • Histidyl residues are derivatized by reaction with diethylpyrocarbonate at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain.
  • Para-bromophenacyl bromide also is useful; the reaction is preferably performed in 0.1 M sodium cacodylate at pH 6.0.
  • Lysinyl and amino-terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the effect of reversing the charge of the lysinyl residues.
  • Other suitable reagents for derivatizing alpha-amino-containing residues include imidoesters such as methyl picolinimidate, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O-methylisourea, 2,4-pentanedione, and transaminase-catalyzed reaction with glyoxylate.
  • Arginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pK a of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.
  • tyrosyl residues may be made, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane.
  • aromatic diazonium compounds or tetranitromethane Most commonly, N-acetylimidizole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.
  • R and R' are different alkyl groups, such as 1-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide.
  • aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.
  • Sugar(s) may be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of tyrosine, or tryptophan, or (f) the amide group of glutamine.
  • conjugate moieties that can be linked to any of the glucagon antagonists described herein include but are not limited to a heterologous peptide or polypeptide (including for example, a plasma protein), a targeting agent, an immunoglobulin or portion thereof (e.g. variable region, CDR, or Fc region), a diagnostic label such as a radioisotope, fluorophore or enzymatic label, a polymer including water soluble polymers, or other therapeutic or diagnostic agents.
  • a conjugate comprising a glucagon antagonist of the present invention and a plasma protein, wherein the plasma protein is selected form the group consisting of albumin, transferin, fibrinogen and globulins.
  • the linker comprises a chain of atoms from 1 to about 60, or 1 to 30 atoms or longer, 2 to 5 atoms, 2 to 10 atoms, 5 to 10 atoms, or 10 to 20 atoms long.
  • the chain atoms are all carbon atoms.
  • the chain atoms in the backbone of the linker are selected from the group consisting of C, O, N, and S. Chain atoms and linkers may be selected according to their expected solubility (hydrophilicity) so as to provide a more soluble conjugate.
  • the linker provides a functional group that is subject to cleavage by an enzyme or other catalyst or hydrolytic conditions found in the target tissue or organ or cell.
  • the length of the linker is long enough to reduce the potential for steric hindrance.
  • the linker is a covalent bond or a peptidyl bond and the conjugate is a polypeptide
  • the entire conjugate can be a fusion protein.
  • peptidyl linkers may be any length. Exemplary linkers are from about 1 to 50 amino acids in length, 5 to 50, 3 to 5, 5 to 10, 5 to 15, or 10 to 30 amino acids in length.
  • Such fusion proteins may alternatively be produced by recombinant genetic engineering methods known to one of ordinary skill in the art.
  • the glucagon antagonists are conjugated, e.g., fused to an immunoglobulin or portion thereof (e.g. variable region, CDR, or Fc region).
  • immunoglobulins e.g. variable region, CDR, or Fc region.
  • immunoglobulins include IgG, IgA, IgE, IgD or IgM.
  • the Fc region is a C-terminal region of an Ig heavy chain, which is responsible for binding to Fc receptors that carry out activities such as recycling (which results in prolonged half-life), antibody dependent cell-mediated cytotoxicity (ADCC), and complement dependent cytotoxicity (CDC).
  • the human IgG heavy chain Fc region stretches from Cys226 to the C-terminus of the heavy chain.
  • the "hinge region” generally extends from Glu216 to Pro230 of human IgG1 (hinge regions of other IgG isotypes may be aligned with the IgG1 sequence by aligning the cysteines involved in cysteine bonding).
  • the Fc region of an IgG includes two constant domains, CH2 and CH3.
  • the CH2 domain of a human IgG Fc region usually extends from amino acids 231 to amino acid 341.
  • the CH3 domain of a human IgG Fc region usually extends from amino acids 342 to 447.
  • the Fc region may comprise one or more native or modified constant regions from an immunoglobulin heavy chain, other than CH1, for example, the CH2 and CH3 regions of IgG and IgA, or the CH3 and CH4 regions of IgE.
  • Suitable conjugate moieties include portions of immunoglobulin sequence that include the FcRn binding site.
  • FcRn a salvage receptor, is responsible for recycling immunoglobulins and returning them to circulation in blood.
  • the region of the Fc portion of IgG that binds to the FcRn receptor has been described based on X-ray crystallography ( Burffle et al. 1994, Nature 372:379 ).
  • the major contact area of the Fc with the FcRn is near the junction of the CH2 and CH3 domains.
  • Fc-FcRn contacts are all within a single Ig heavy chain.
  • the major contact sites include amino acid residues 248, 250-257, 272, 285, 288, 290-291, 308-311, and 314 of the CH2 domain and amino acid residues 385-387, 428, and 433-436 of the CH3 domain.
  • Fc ⁇ R are responsible for ADCC and CDC.
  • positions within the Fc region that make a direct contact with Fc ⁇ R are amino acids 234-239 (lower hinge region), amino acids 265-269 (B/C loop), amino acids 297-299 (C'/E loop), and amino acids 327-332 (F/G) loop ( Sondermann et al., Nature 406: 267-273, 2000 ).
  • the lower hinge region of IgE has also been implicated in the FcRI binding ( Henry, et al., Biochemistry 36, 15568-15578, 1997 ).
  • Residues involved in IgA receptor binding are described in Lewis et al., (J Immunol. 175:6694-701, 2005 ). Amino acid residues involved in IgE receptor binding are described in Sayers et al. (J Biol Chem. 279(34):35320-5, 2004 ).
  • Amino acid modifications may be made to the Fc region of an immunoglobulin.
  • Such variant Fc regions comprise at least one amino acid modification in the CH3 domain of the Fc region (residues 342-447) and/or at least one amino acid modification in the CH2 domain of the Fc region (residues 231-341).
  • Mutations believed to impart an increased affinity for FcRn include T256A, T307A, E380A, and N434A ( Shields et al. 2001, J. Biol. Chem. 276:6591 ).
  • Other mutations may reduce binding of the Fc region to FcyRI, Fc ⁇ RIIA, Fc ⁇ RIIB, and/or Fc ⁇ RIIIA without significantly reducing affinity for FcRn.
  • substitution of the Asn at position 297 of the Fc region with Ala or another amino acid removes a highly conserved N-glycosylation site and may result in reduced immunogenicity with concomitant prolonged half-life of the Fc region, as well as reduced binding to Fc ⁇ Rs ( Routledge et al. 1995, Transplantation 60:847 ; Friend et al. 1999, Transplantation 68:1632 ; Shields et al. 1995, J. Biol. Chem. 276:6591 ).
  • Amino acid modifications at positions 233-236 of IgG1 have been made that reduce binding to Fc ⁇ Rs ( Ward and Ghetie 1995, Therapeutic Immunology 2:77 and Armour et al. 1999, Eur. J. Immunol. 29:2613 ).
  • Some exemplary amino acid substitutions are described in US Patents 7,355,008 and 7,381,408 , each incorporated by reference herein in its entirety.
  • the present disclosure also encompasses glucagon fusion peptides or proteins wherein a second peptide or polypeptide has been fused to a terminus, e.g., the carboxy terminus of the glucagon antagonist.
  • the second peptide added to the carboxy terminus of the glucagon antagonist is GPSSGAPPPS, KRNRNNIA or KRNR linked to amino acid 29 of the glucagon antagonist (according to the amino acid numbering of wild type glucagon).
  • the second peptide is XGPSSGAPPPS, wherein X is selected from one of the 20 common amino acids, e.g., glutamic acid, aspartic acid or glycine.
  • X represents an amino acid, for example Cys, that further comprises a hydrophilic moiety covalently linked to the side chain of that amino acid.
  • C-terminal extensions improve solubility and also can improve glucagon or GLP-1 activity.
  • the glucagon antagonist further comprises a carboxy terminal extension, the carboxy terminal amino acid of the extension ends in an amide group or an ester group rather than a carboxylic acid.
  • the threonine at position 29 (according to the amino acid numbering of wild type glucagon) is replaced with a glycine.
  • a glucagon antagonist having a glycine substitution for threonine at position 29 and comprising the C-terminal extension of GPSSGAPPPS is four times as potent at the GLP-1 receptor as native glucagon modified to comprise the same C-terminal extension.
  • This T29G substitution can be used in conjunction with other modifications disclosed herein to enhance the affinity of the glucagon antagonists for the GLP-1 receptor.
  • an amino acid is added to the C-terminus, and the additional amino acid is selected from the group consisting of glutamic acid, aspartic acid and glycine.
  • the present disclosure also encompasses multimers of the modified glucagon antagonists disclosed herein.
  • Two or more of the modified glucagon antagonists can be linked together using standard linking agents and procedures known to those skilled in the art.
  • dimers can be formed between two modified glucagon antagonists through the use of bifunctional thiol crosslinkers and bi-functional amine crosslinkers, particularly for the glucagon antagonists that have been substituted with cysteine, lysine ornithine, homocysteine or acetyl phenylalanine residues.
  • the glucagon antagonists disclosed herein are modified to comprise an acyl group or alkyl group.
  • Acylation or alkylation can increase the half-life of the glucagon antagonists in circulation.
  • Acylation or alkylation can advantageously delay the onset of action and/or extend the duration of action at the glucagon and/or GLP-1 receptors and/or improve resistance to proteases such as DPP-IV and/or improve solubility.
  • the potency of the acylated glucagon antagonists is comparable to the unacylated versions of the glucagon antagonists.
  • Glucagon antagonists may be acylated or alkylated at the same amino acid position where a hydrophilic moiety is linked, or at a different amino acid position.
  • the invention provides a glucagon antagonist modified to comprise an acyl group or alkyl group covalently linked to the amino acid at position 10 of the glucagon antagonist (according to the amino acid numbering of wild type glucagon).
  • the glucagon antagonist may further comprise a spacer between the amino acid at position 10 of the glucagon antagonist and the acyl group or alkyl group.
  • the acyl group is a fatty acid or bile acid, or salt thereof, e.g.
  • the spacer is any moiety with suitable reactive groups for attaching acyl or alkyl groups.
  • the spacer comprises an amino acid, a dipeptide, or a tripeptide, or a hydrophilic bifunctional spacer.
  • the spacer is selected from the group consisting of: Trp, Glu, Asp, Cys and a spacer comprising NH 2 (CH 2 CH 2 O)n(CH 2 )mCOOH, wherein m is any integer from 1 to 6 and n is any integer from 2 to 12.
  • acylated or alkylated glucagon antagonists may also further comprise a hydrophilic moiety, optionally a polyethylene glycol. Any of the foregoing glucagon antagonists may comprise two acyl groups or two alkyl groups, or a combination thereof.
  • Acylation can be carried out at any positions within the glucagon antagonist, including any of positions 1-29, a position within a C-terminal extension, or the C-terminal amino acid, provided that glucagon antagonist activity (and optionally GLP-1 activity) is retained.
  • Nonlimiting examples include positions 5, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 24, 27, 28, or 29 (according to the amino acid numbering of wild type glucagon).
  • the acyl group can be covalently linked directly to an amino acid of the glucagon antagonist, or indirectly to an amino acid of the glucagon antagonist via a spacer, wherein the spacer is positioned between the amino acid of the glucagon antagonist and the acyl group.
  • Glucagon antagonists may be acylated at the same amino acid position where a hydrophilic moiety is linked, or at a different amino acid position.
  • Nonlimiting examples include acylation at position 10 (according to the amino acid numbering of wild type glucagon) and pegylation at one or more positions in the C-terminal portion of the glucagon antagonist, e.g., position 24, 28 or 29 (according to the amino acid numbering of wild type glucagon), within a C-terminal extension, or at the C-terminus (e.g., through adding a C-terminal Cys).
  • the glucagon antagonist is modified to comprise an acyl group by direct acylation of an amine, hydroxyl, or thiol of a side chain of an amino acid of the glucagon antagonist.
  • the glucagon antagonist is directly acylated through the side chain amine, hydroxyl, or thiol of an amino acid.
  • acylation is at position 10, 20, 24, or 29 (according to the amino acid numbering of wild type glucagon).
  • the acylated glucagon antagonist can comprise the amino acid sequence of SEQ ID NO : 2, or a modified amino acid sequence thereof comprising one or more of the amino acid modifications described herein, with at least one of the amino acids at positions 10, 20, 24, and 29 (according to the amino acid numbering of wild type glucagon) modified to any amino acid comprising a side chain amine, hydroxyl, or thiol.
  • the direct acylation of the glucagon antagonist occurs through the side chain amine, hydroxyl, or thiol of the amino acid at position 10 (according to the amino acid numbering of wild type glucagon).
  • the amino acid comprising a side chain amine is an amino acid of Formula I:
  • the amino acid of Formula I is the amino acid wherein n is 4 (Lys) or n is 3 (Orn).
  • the amino acid comprising a side chain hydroxyl is an amino acid of Formula II:
  • the amino acid of Formula II is the amino acid wherein n is 1 (Ser).
  • the amino acid comprising a side chain thiol is an amino acid of Formula III:
  • the amino acid of Formula II is the amino acid wherein n is 1 (Cys).
  • the acylated glucagon antagonist comprises a spacer between the antagonist and the acyl group.
  • the glucagon antagonist is covalently bound to the spacer, which is covalently bound to the acyl group.
  • the glucagon antagonist is modified to comprise an acyl group by acylation of an amine, hydroxyl, or thiol of a spacer, which spacer is attached to a side chain of an amino acid at position 10, 20, 24, or 29 (according to the amino acid numbering of wild type glucagon), or at the C-terminal amino acid of the glucagon antagonist.
  • the amino acid to which the spacer is attached can be any amino acid comprising a moiety which permits linkage to the spacer.
  • an amino acid comprising a side chain NH2, -OH, or -COOH e.g., Lys, Orn, Ser, Asp, or Glu
  • the acylated glucagon antagonist can comprise the amino acid sequence of SEQ ID NO: 1, or a modified amino acid sequence thereof comprising one or more of the amino acid modifications described herein, with at least one of the amino acids at positions 10, 20, 24, and 29 (according to the amino acid numbering of wild type glucagon) modified to any amino acid comprising a side chain amine, hydroxyl, or carboxylate.
  • the spacer is an amino acid comprising a side chain amine, hydroxyl, or thiol, or a dipeptide or tripeptide comprising an amino acid comprising a side chain amine, hydroxyl, or thiol.
  • the acylation can occur through the alpha amine of the amino acid or a side chain amine.
  • the spacer amino acid can be any amino acid.
  • the spacer amino acid can be a hydrophobic amino acid, e.g., Gly, Ala, Val, Leu, Ile, Trp, Met, Phe, Tyr.
  • the spacer amino acid can be an acidic residue, e.g., Asp and Glu.
  • the spacer amino acid is an amino acid comprising a side chain amine, e.g., an amino acid of Formula I (e.g., Lys or Orn).
  • an amino acid of Formula I e.g., Lys or Orn
  • both the alpha amine and the side chain amine of the spacer amino acid to be acylated, such that the glucagon antagonist is diacylated.
  • Embodiments of the invention include such diacylated molecules.
  • the amino acid or one of the amino acids of the dipeptide or tripeptide can be an amino acid of Formula II.
  • the amino acid is Ser.
  • the amino acid or one of the amino acids of the dipeptide or tripeptide can be an amino acid of Formula III.
  • the amino acid is Cys.
  • the spacer comprises a hydrophilic bifunctional spacer.
  • the spacer comprises an amino poly(alkyloxy)carboxylate.
  • the spacer can comprise, for example, NH 2 (CH 2 CH 2 O) n (CH 2 ) m COOH, wherein m is any integer from 1 to 6 and n is any integer from 2 to 12, such as, e.g., 8-amino-3,6-dioxaoctanoic acid, which is commercially available from Peptides International, Inc. (Louisville, KY).
  • Suitable methods of peptide acylation via amines, hydroxyls, and thiols are known in the art. See, for example, Example 19 (for methods of acylating through an amine), Miller, Biochem Biophys Res Commun 218: 377-382 (1996 ); Shimohigashi and Stammer, Int J Pept Protein Res 19: 54-62 (1982 ); and Previero et al., Biochim Biophys Acta 263: 7-13 (1972 ) (for methods of acylating through a hydroxyl); and San and Silvius, J Pept Res 66: 169-180 (2005 ) (for methods of acylating through a thiol); Bioconjugate Chem.
  • the acyl group of the acylated glucagon antagonist can be of any size, e.g., any length carbon chain, and can be linear or branched.
  • the acyl group is a C4 to C30 fatty acid.
  • the acyl group can be any of a C4 fatty acid, C6 fatty acid, C8 fatty acid, C10 fatty acid, C12 fatty acid, C14 fatty acid, C16 fatty acid, C18 fatty acid, C20 fatty acid, C22 fatty acid, C24 fatty acid, C26 fatty acid, C28 fatty acid, or a C30 fatty acid.
  • the acyl group is a C8 to C20 fatty acid, e.g., a C14 fatty acid or a C16 fatty acid.
  • the acyl group is a bile acid.
  • the bile acid can be any suitable bile acid, including, but not limited to, cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid, taurocholic acid, glycocholic acid, and cholesterol acid.
  • the acylated glucagon antagonist can comprise SEQ ID NO: 1, including any of the modifications described herein, in which (a) at least one of the amino acids at position 10, 20, 24, and 29 (according to the amino acid numbering of wild type glucagon) comprise an acyl group and (b) at least one of the amino acids at position 16, 17, 21, 24, or 29 (according to the amino acid numbering of wild type glucagon), a position within a C-terminal extension, or the C-terminal amino acid are modified to a Cys, Lys, Orn, homo-Cys, or Ac-Phe, and the side chain of the amino acid is covalently bonded to a hydrophilic moiety (e.g., PEG).
  • a hydrophilic moiety e.g., PEG
  • the acyl group is attached to position 10 (according to the amino acid numbering of wild type glucagon), optionally via a spacer comprising Cys, Lys, Orn, homo-Cys, or Ac-Phe, and the hydrophilic moiety is incorporated at a Cys residue at position 24 (according to the amino acid numbering of wild type glucagon).
  • the acylated glucagon antagonist can comprise a spacer, wherein the spacer is both acylated and modified to comprise the hydrophilic moiety.
  • suitable spacers include a spacer comprising one or more amino acids selected from the group consisting of Cys, Lys, Orn, homo-Cys, and Ac-Phe.
  • the glucagon antagonist is modified to comprise an alkyl group which is attached to the glucagon antagonist via an ester, ether, thioether, amide, or alkyl amine linkage for purposes of prolonging half-life in circulation and/or delaying the onset of and/or extending the duration of action and/or improving resistance to proteases such as DPP-IV.
  • Alkylation can be carried out at any positions within the glucagon antagonist, including any of positions 1-29, a position within a C-terminal extension, or the C-terminal amino acid, provided that the glucagon antagonist activity (and optionally GLP-1 activity) is retained.
  • Nonlimiting examples include positions 5, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 24, 27, 28, or 29 (according to the amino acid numbering of wild type glucagon).
  • the alkyl group can be covalently linked directly to an amino acid of the glucagon antagonist, or indirectly to an amino acid of the glucagon antagonist via a spacer, wherein the spacer is positioned between the amino acid of the glucagon antagonist and the alkyl group.
  • Glucagon antagonists may be alkylated at the same amino acid position where a hydrophilic moiety is linked, or at a different amino acid position.
  • Nonlimiting examples include alkylation at position 10 (according to the amino acid numbering of wild type glucagon) and pegylation at one or more positions in the C-terminal portion of the glucagon antagonist, e.g., position 24, 28 or 29 (according to the amino acid numbering of wild type glucagon), within a C-terminal extension, or at the C-terminus (e.g., through adding a C-terminal Cys).
  • the glucagon antagonist is modified to comprise an alkyl group by direct alkylation of an amine, hydroxyl, or thiol of a side chain of an amino acid of the glucagon antagonist.
  • the glucagon antagonist is directly alkylated through the side chain amine, hydroxyl, or thiol of an amino acid.
  • alkylation is at position 10, 20, 24, or 29 (according to the amino acid numbering of wild type glucagon).
  • the alkylated glucagon antagonist can comprise the amino acid sequence of SEQ ID NO : 2, or a modified amino acid sequence thereof comprising one or more of the amino acid modifications described herein, with at least one of the amino acids at positions 10, 20, 24, and 29 (according to the amino acid numbering of wild type glucagon) modified to any amino acid comprising a side chain amine, hydroxyl, or thiol.
  • the direct alkylation of the glucagon antagonist occurs through the side chain amine, hydroxyl, or thiol of the amino acid at position 10 (according to the amino acid numbering of wild type glucagon).
  • the amino acid comprising a side chain amine is an amino acid of Formula I.
  • the amino acid of Formula I is the amino acid wherein n is 4 (Lys) or n is 3 (Orn).
  • the amino acid comprising a side chain hydroxyl is an amino acid of Formula II.
  • the amino acid of Formula II is the amino acid wherein n is 1 (Ser).
  • the amino acid comprising a side chain thiol is an amino acid of Formula III.
  • the amino acid of Formula II is the amino acid wherein n is 1 (Cys).
  • the alkylated glucagon antagonist comprises a spacer between the antagonist and the alkyl group.
  • the glucagon antagonist is covalently bound to the spacer, which is covalently bound to the alkyl group.
  • the glucagon antagonist is modified to comprise an alkyl group by alkylation of an amine, hydroxyl, or thiol of a spacer, which spacer is attached to a side chain of an amino acid at position 10, 20, 24, or 29 of the glucagon antagonist (according to the amino acid numbering of wild type glucagon).
  • the amino acid to which the spacer is attached can be any amino acid comprising a moiety which permits linkage to the spacer.
  • an amino acid comprising a side chain NH2, -OH, or -COOH e.g., Lys, Orn, Ser, Asp, or Glu
  • the alkylated glucagon antagonist can comprise the amino acid sequence of SEQ ID NO: 1, or a modified amino acid sequence thereof comprising one or more of the amino acid modifications described herein, with at least one of the amino acids at positions 10, 20, 24, and 29 (according to the amino acid numbering of wild type glucagon) modified to any amino acid comprising a side chain amine, hydroxyl, or carboxylate.
  • the spacer is an amino acid comprising a side chain amine, hydroxyl, or thiol or a dipeptide or tripeptide comprising an amino acid comprising a side chain amine, hydroxyl, or thiol.
  • the alkylation can occur through the alpha amine of the amino acid or a side chain amine.
  • the spacer amino acid can be any amino acid.
  • the spacer amino acid can be a hydrophobic amino acid, e.g., Gly, Ala, Val, Leu, Ile, Trp, Met, Phe, Tyr.
  • the spacer amino acid can be an acidic residue, e.g., Asp and Glu.
  • the spacer amino acid is an amino acid comprising a side chain amine, e.g., an amino acid of Formula I (e.g., Lys or Orn).
  • an amino acid of Formula I e.g., Lys or Orn
  • both the alpha amine and the side chain amine of the spacer amino acid to be alkylated, such that the glucagon antagonist is dialkylated.
  • Embodiments of the invention include such dialkylated molecules.
  • the amino acid or one of the amino acids of the dipeptide or tripeptide can be an amino acid of Formula II.
  • the amino acid is Ser.
  • the amino acid or one of the amino acids of the dipeptide or tripeptide can be an amino acid of Formula III.
  • the amino acid is Cys.
  • the spacer comprises a hydrophilic bifunctional spacer.
  • the spacer comprises an amino poly(alkyloxy)carboxylate.
  • the spacer can comprise, for example, NH 2 (CH 2 CH 2 O) n (CH 2 ) m COOH, wherein m is any integer from 1 to 6 and n is any integer from 2 to 12, such as, e.g., 8-amino-3,6-dioxaoctanoic acid, which is commercially available from Peptides International, Inc. (Louisville, KY).
  • Suitable methods of peptide alkylation via amines, hydroxyls, and thiols are known in the art.
  • a Williamson ether synthesis can be used to form an ether linkage between the glucagon antagonist and the alkyl group.
  • a nucleophilic substitution reaction of the peptide with an alkyl halide can result in any of an ester, ether, thioether, amide, or alkyl amine linkage.
  • the alkyl group comprises a steroid moiety of a bile acid, e.g., cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid, taurocholic acid, glycocholic acid, and cholesterol acid.
  • a bile acid e.g., cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid, taurocholic acid, glycocholic acid, and cholesterol acid.
  • the alkylated glucagon antagonists described herein can be further modified to comprise a hydrophilic moiety.
  • the hydrophilic moiety can comprise a polyethylene glycol (PEG) chain.
  • PEG polyethylene glycol
  • the alkylated glucagon antagonist can comprise SEQ ID NO: 1, or a modified amino acid sequence thereof comprising one or more of the amino acid modifications described herein, in which (a) at least one of the amino acids at position 10, 20, 24, and 29 (according to the amino acid numbering of wild type glucagon) comprise an alkyl group and (b) at least one of the amino acids at position 16, 17, 21, 24, and 29 (according to the amino acid numbering of wild type glucagon), a position within a C-terminal extension or the C-terminal amino acid are modified to a Cys, Lys, Orn, homo-Cys, or Ac-Phe, and the side chain of the amino acid is covalently bonded to a hydrophilic moiety (e.g., PEG).
  • a hydrophilic moiety e.g., PEG
  • the alkyl group is attached to position 10 (according to the amino acid numbering of wild type glucagon), optionally via a spacer comprising Cys, Lys, Orn, homo-Cys, or Ac-Phe, and the hydrophilic moiety is incorporated at a Cys residue at position 24 (according to the amino acid numbering of wild type glucagon).
  • the alkylated glucagon antagonist can comprise a spacer, wherein the spacer is both alkylated and modified to comprise the hydrophilic moiety.
  • suitable spacers include a spacer comprising one or more amino acids selected from the group consisting of Cys, Lys, Orn, homo-Cys, and Ac-Phe.
  • the compounds of this invention may be prepared by standard synthetic methods, recombinant DNA techniques, or any other methods of preparing peptides and fusion proteins. Although certain non-natural amino acids cannot be expressed by standard recombinant DNA techniques, techniques for their preparation are known in the art. Compounds of this invention that encompass non-peptide portions may be synthesized by standard organic chemistry reactions, in addition to standard peptide chemistry reactions when applicable.
  • Glucagon analogs were synthesized using HBTU-activated "Fast Boc" single coupling starting from 0.2mmole of Boc Thr(OBzl)Pam resin on a modified Applied Biosystem 430 A peptide synthesizer. Boc amino acids and HBTU were obtained from Midwest Biotech (Fishers, IN). Side chain protecting groups used were: Arg(Tos), Asn(Xan), Asp(OcHex), Cys(pMeBzl), His(Bom), Lys(2Cl-Z), Ser(OBzl), Thr(OBzl), Tyr(2Br-Z), and Trp(CHO). The side-chain protecting group on the N-terminal His was Boc.
  • Each completed peptidyl resin was treated with a solution of 20% piperdine in dimethylformamide to remove the formyl group from the tryptophan.
  • Liquid hydrogen fluoride cleavages were performed in the presence of p-cresol and dimethyl sulfide. The cleavage was run for 1 hour in an ice bath using an HF apparatus (Penninsula Labs). After evaporation of the HF, the residue was suspended in diethyl ether and the solid materials were filtered.
  • the glucagon Cys analog is dissolved in phosphate buffered saline (5-10mg/ml) and 0.01M ethylenediamine tetraacetic acid is added (10-15% of total volume).
  • 0.01M ethylenediamine tetraacetic acid is added and the reaction stirred at room temp while monitoring reaction progress by HPLC.
  • the reaction mixture is acidified and loaded onto a preparative reverse phase column for purification using 0.1%TFA/acetonitrile gradient. The appropriate fractions were combined and lyophilized to give the desired pegylated derivatives.
  • the fractions containing the purest product (48-52) were combined frozen, and lyophilized to give 30.1mg.
  • An HPLC analysis of the product demonstrated a purity of >90% and MALDI mass spectral analysis demonstrated the desired mass of 3429.7.
  • Glucagon Cys 21 , Glucagon Cys 24 , and Glucagon Cys 29 were similarly prepared.
  • Glucagon Cys 17 15.1mg of Glucagon Cys 17 (1-29) and 27.3mg methoxy poly(ethyleneglycol) maleimide avg. M.W.5000 (mPEG-Mal-5000,Nektar Therapeutics) were dissolved in 3.5ml phosphate buffered saline (PBS) and 0.5ml 0.01M ethylenediamine tetraacetic acid (EDTA) was added.
  • PBS phosphate buffered saline
  • EDTA ethylenediamine tetraacetic acid
  • the reaction mixture was loaded onto 2.2 x 25 cm Kromasil C18 preparastive reverse phase column.
  • An acetonitrile gradient was run on a Pharmacia FPLC while monitoring the UV wavelength at 214nm and collecting 5 min fractions.
  • the fractions corresponding to product were combined, frozen and lyophilized to give 45.8mg.
  • MALDI mass spectral analysis showed a typical PEG broad signal with a maximum at 9175.2 which is approximately 5,000 a.m.u. more than Glucagon C 24 (3457.8).
  • a buffer 0.1%TFA
  • B buffer 0.1%TFA/50%ACN
  • flow 4ml/min
  • 5 min fractions were collected while monitoring the UV at 214nm (2.0A).
  • the fractions containing homogeneous product were combined, frozen and lyophilized to give 25.7 mg.
  • Purity as determined by analytical HPLC was ⁇ 90%.
  • a MALDI mass spectral analysis showed a broad peak from 23,000 to 27,000 which is approximately 20,000 a.m.u. more than starting Glucagon C 24 (3457.8).
  • Glucagon Cys 24 (1-29) was added 4ml 0.05M ammonium bicarbonate/50%acetonitrile and 5.5 ul of a solution of 2-bromo-4-hydroxybutyric acid- ⁇ -lactone (100ul in 900ul acetonitrile). After 3hrs of stirring at room temperature, another 105 ul of lactone solution was added to the reaction mixture which was stirred another 15hrs. The reaction mixture was diluted to 10ml with 10% aqueous acetic acid and was loaded onto a 2.2 x 25 cm Kromasil C18 preparative reverse phase column.
  • a solution (1mg/ml or 3mg/ml) of glucagon (or an analog) is prepared in 0.01N HCl.
  • 100ul of stock solution is diluted to 1ml with 0.01N HCl and the UV absorbance (276nm) is determined.
  • the pH of the remaining stock solution is adjusted to pH7 using 200-250ul 0.1M Na 2 HPO 4 (pH9.2).
  • the solution is allowed to stand overnight at 4°C then centrifuged. 100ul of supernatant is then diluted to 1ml with 0.01N HCl, and the UV absorbance is determined (in duplicate).
  • the affinity of peptides to the glucagon receptor was measured in a competition binding assay utilizing scintillation proximity assay technology.
  • Serial 3-fold dilutions of the peptides made in scintillation proximity assay buffer (0.05 M Tris-HCl, pH 7.5, 0.15 M NaCl, 0.1% w/v bovine serum albumin) were mixed in 96 well white/clear bottom plate (Corning Inc., Acton, MA) with 0.05 nM (3-[ 125 I]-iodotyrosyl) Tyr10 glucagon (Amersham Biosciences, Piscataway, NJ), 1-6 micrograms per well, plasma membrane fragments prepared from cells over-expressing human glucagon receptor, and 1 mg/well polyethyleneimine-treated wheat germ agglutinin type A scintillation proximity assay beads (Amersham Biosciences, Piscataway, NJ).
  • % Specific Binding ((Bound-NSB)/(Total bound- NSB)) X 100. IC 50 values were determined by using Origin software (OriginLab, Northampton, MA).
  • glucagon analogs to induce cAMP was measured in a firefly luciferase-based reporter assay.
  • HEK293 cells co-transfected with either glucagon- or GLP-1 receptor and luciferase gene linked to cAMP responsive element were serum deprived by culturing 16h in DMEM (Invitrogen, Carlsbad, CA) supplemented with 0.25% Bovine Growth Serum (HyClone, Logan, UT) and then incubated with serial dilutions of either glucagon, GLP-1 or novel glucagon analogs for 5 h at 37°C, 5% CO 2 in 96 well poly-D-Lysine-coated "Biocoat” plates (BD Biosciences, San Jose, CA).
  • glucagon analog was dissolved in water or PBS and an initial HPLC analysis was conducted. After adjusting the pH (4, 5, 6, 7), the samples were incubated over a specified time period at 37°C and re-analyzed by HPLC to determine the integrity of the peptide. The concentration of the specific peptide of interest was determined and the percent remaining intact was calculated relative to the initial analysis. Results for Glucagon Cys 21 -maleimidoPEG 5K are shown in Figs. 1 and 2 .
  • glucagon antagonists were synthesized using the following general strategies:
  • Glucagon analogs were synthesized using HBTU-activated "Fast Boc" single coupling starting from 0.2mmole of MBHA resin or first amino acid attached Pam resin on a modified Applied Biosystem 430A peptide synthesizer. Boc amino acids and HBTU were obtained from Midwest Biotech (Fishers, IN). Side chain protecting groups used were: Arg(Tos), Asn(Xan), Asp(OcHex), Cys(pMeBzl), His(Bom), Lys(2Cl-Z), Ser(OBzl), Thr(OBzl), Tyr(2Br-Z), and Trp(CHO).
  • each completed peptidyl resin was treated with 20% piperdine/DMF to remove the formyl group from the tryptophan.
  • Liquid hydrogen fluoride cleavages were performed in the presence of p-cresol and dimethyl sulfide. The cleavage was run for 1 hour in an ice bath using an HF apparatus (Penninsula Labs). After evaporation of the HF, the residue was suspended in diethyl ether and the solid materials were filtered. Each peptide was extracted into 30-70ml aqueous acetic acid and diluted with water and lyophilized. Crude peptide was analyzed by analytical HPLC and Peptide molecule weight was checked by ESI or MALDI-TOF mass spectrometry. Peptide was purified by the general HPLC purification procedure.
  • Peptides were synthesized on an ABI 433A automated peptide synthesizer using standard Fmoc chemistry with Rink MBHA amide resin or first amino acid attached Wang resin (Novabiochem, San Diego, CA) using DIC/HOBT as coupling reagent. 3-phenyllactic acid (PLA) was coupled manually by BEPBT after the automated peptide synthesis.
  • Fmoc-Cys(SO3Na)-OH and Fmoc-homoCys(SO3Na)-OH were used for the synthesis of the cysteic acid and homocysteic acid containing peptides.
  • Peptides were cleaved from the resin with cleavage cocktail containing 85%TFA, 5% phenol, 5% water and 5% thioanisole (2.5% EDT was added when peptide contains Cysteine). Crude peptides were precipitated in ether, centrifuged, and lyophilized. Peptide was analyzed by analytical HPLC and checked by ESI or MALDI-TOF mass spectrometry. Peptide was purified by the general HPLC purification procedure.
  • the peptides were typically purified on a Waters 600E connected 486 monitor systems with semi-prepare HPLC column (ZORBAX SB-C8, 21.2x250mm, 7 ⁇ m, Agilent) monitored at 214nm or 230nM.
  • the gradients used for the purification were 0-30%B over 40 min, then 30-50%B over 30min at a flow rate of 12ml/min if not specifically noted.
  • Fractions were analyzed by analytical HPLC and checked by mass spectrometry. The fractions over 90% pure were collected, lyophilized and stored. The fractions with purity between 60-90% were combined, lyophilized and purified again.
  • Pegylated glucagon analog deriviatives were prepared in accordance with the following general Cys-maleimido procedure. Typically, the glucagon Cys analog is dissolved in phosphate buffered saline (5-10mg/ml) and 0.01M ethylenediamine tetraacetic acid is added (10-15% of total volume). Excess (1.5 ⁇ 2-fold) maleimido methoxyPEG reagent (Nektar, Huntsville, AL) is added and the reaction stirred at room temp while monitoring reaction progress by HPLC. After 2-24hrs, the reaction mixture, is acidified and loaded onto a preparative reverse phase column for purification using 0.1 %TFA/acetonitrile gradients.
  • the appropriate fractions were combined and lyophilized to give the desired pegylated derivatives.
  • the peptides were dissolved in 25% acetonitrile water or 4 ⁇ 6M urea buffer with 0.1M Tris (adjust pH 8.0-8.5) and reacted with PEG reagents.
  • the aqueous eluate was lyophilized to yield a viscous amorphous Fmoc-homoCys(SO 3 H)-OH (1.6g, 3.95mmole, yield 79.2%).
  • the above free acid was then added 50ml water containing 0.16g (4mmole) NaOH in ice bath and lyophilized to get quantitative Fmoc-homoCys(SO 3 Na)-OH which can be used directly in SPPS without further purification.
  • the amorphous lyophilized Fmoc-homoCys(SO 3 Na)-OH is recrystallined in ethanol/acetate ester(2:1) to yield a crystalline solid product with m.p. of 215-218°C and ESI-MS 404.2[(M-H) + , acid form]
  • a peptide sequence TSEYSKYLDSRRAQDFVQWLMNT (SEQ ID NO: 51; [E3]glucagon(7-29)) was first solid phase synthesized on ABI 433A automated peptide synthesizer using 0.1mmole Fmoc/HOBT/DCC chemistry program with 0.1mmole Rink MBHA amide resin using DIC/HOBT as coupling reagent.
  • Fmoc amino acid Ala, Arg(Pmc), Asp(OtBu), Asn(Trt), Glu(OtBu), Gln(Trt), Leu, Lys(Boc), Met, PLA, Ser(tBu), Thr(tBu), Trp(Boc), Tyr(tBu), and Val.
  • the peptidyl resin was coupled manually with 3-phenyllactic acid (83mg, 0.5mmole) and DEPBT (150mg, 0.5mmole) in 4ml 5%DIEA/DMF for about 2h to obtain the peptidyl resin with the following sequence: HO-PLA-Thr-Ser-Glu-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-NH 2 (SEQ ID NO: 50).
  • Peptidyl resin was treated with 8.5ml TFA with addition of 0.5g phenol, 0.5ml water and 0.5ml thioanisole at room temperature for about 2hs.
  • the peptide dissolved in TFA was filtered and 40ml ether was added to precipitate the peptide.
  • the crude peptide were centrifuged, dissolved in aqueous acetic acid and lyophilized. Crude peptide yield was 200 ⁇ 250mg and after purification the yield was 25 ⁇ 40mg (10 ⁇ 15% yield totally) peptide with 95% purity.
  • the peptide was analyzed in general analytical HPLC showing retention time as 7.66min and ESI-MS analysis demonstrated the desired mass of 2986.0 corresponding with the peptide molecular weight 2986.3.
  • a peptide sequence YSKYLDSRRAQDFVQWLMNT (SEQ ID NO: 51; glucagon(10-29)) was first solid phase synthesized on ABI 433A automated peptide synthesizer using 0.1mmole Fmoc/HOBT/DCC chemistry program with 0.1mmole Rink MBHA amide resin using DIC/HOBT as coupling reagent. After the automated synthesis, the peptidyl resin was coupled manually with Fmoc-homoCys(SO3Na)-OH (130mg; 0.3mmole), HOBT (45.2mg, 0.33mole) and DIC (52.0ul, 0.33mole) in 4ml DMF for about 2h.
  • Fmoc amino acid Ala, Arg(Pmc), Asp(OtBu), Asn(Trt), Gln(Trt), homoCys(SO3Na), Leu, Lys(Boc), Met, Phe, Ser(tBu), Thr(tBu), Trp(Boc), Tyr(tBu), and Val.
  • Peptidyl resin was treated with 8.5ml TFA with addition of 0.5g phenol, 0.5ml water and 0.5ml thioanisole at room temperature for about 2hs.
  • the peptide dissolved in TFA was filtered and 40ml ether was added to precipitate the peptide.
  • the crude peptides were centrifuged, dissolved in aqueous acetic acid and lyophilized. Crude peptide yield was 100 ⁇ 130mg, and after purification 15 ⁇ 20mg (10 ⁇ 15% yield totally) peptide was obtained with 95% purity.
  • the peptide was analyzed in general analytical HPLC shown retention time as 6.73min and ESI-MS analysis demonstrated the desired mass of 3021.0 corresponding with the peptide molecular weight 3021.3.
  • the receptor binding, cAMP induction and cAMP inhibition of glucagon and various glucagon derivative inhibitors were compared.
  • the assays for measuring receptor binding and cAMP induction and cAMP inhibition were conducted using the assay system essentially as disclosed in Examples 12 and 13, respectively.
  • glucagon analogs have been prepared that exhibit glucagon antagonist activity. Such compounds differ from native glucagon in that they do not possess the native N-terminal residues and have a glutamic acid substitution at position 9 relative to native glucagon. Table 4 provides glucagon receptor affinity and antagonist activity for several specific glucagon analog antagonists.
  • Glu 9 is glutamic acid at position 9 according to the numbering of native glucagon.
  • Glucagon receptor binding affinity of glucagon and glucagon peptides modified by truncation of the first amino acid and by substitution at position 9 was analyzed as essentially described in Example 12, The results are shown in Table 6. TABLE 6 peptide no.
  • modified glucagon based peptides tested including the peptides modified at position 9 with Glu, hGlu, CSA-1, CSA-2, and ⁇ -hGlu, exhibited potent glucagon antagonist activity.
  • b pA 2 the negative logarithm of the concentration of the antagonist that reduce the response to 1unit of the agonist to the response obtained from 0.5 unit of agonist.
  • Data are average ⁇ STD for at least two duplicate experiments.
  • c (I/A) 50 the inhibition index, the ratio of inhibitor IC 50 to the added constant glucagon (0.1-0.2nM).
  • Data are average of at least three independent experiments and normalized by the EC 50 d NA, not full antagonist. e ND, not detected.
  • Fig. 3 presents data measuring the binding affinity of glucagon antagonists, where the N-terminus was further shortened with removal of one, three or five amino acids. More particularly, the binding affinity of hCys9-based glucagon antagonists was investigated by measured based on their ability to compete with I 125 labeled glucagon in binding to the glucagon receptor. The results demonstrate that the removal of the first residue reduces affinity but further removal changes the affinity only slightly still yielding a ligand of nanomolar affinity.
  • Fig. 4 presents data demonstrating the ability of select antagonists to suppress glucagon action in a cAMP bioassay.
  • the 5-29 hCys9-based glucagon antagonist was found to be more potent and effective than the literature standards of Glu9 2-29, or the Leu4, Glu9 4-29. Furthermore, the 5-29 or 6-29 hCys9 analogs have exhibited pure potent antagonism, without any measurable agonist activity.
  • Table 8 provides glucagon receptor affinity and antagonist activity for several homocysteic acid modified truncated glucagon fragment analogs.
  • the desHis1-based hCys(S0 3 H) 9 -based antagonist performs as potently as the previously reported Glu 9 - based antagonist [desHis 1 , Glu9]glucagon peptides.
  • the further shortened hCys(SO 3 H) 9 -based glucagon antagonists with removal of three, four or five amino acids were studied.
  • the receptor binding results demonstrate that the removal of the first residue reduces affinity of the compound for the glucagon receptor, but further removal changes the affinity only slightly, and still yields a ligand of nanomolar affinity.
  • Fig. 5A demonstrates that the inability of the 2-29 peptides to fully suppress glucagon action is a function of the residual glucagon agonism that each of these two peptides maintains.
  • glucagon has also been developed where the normally occurring phenylalanine at position six has been substituted with phenyl-lactic acid (PLA), on a 6-29 shortened glucagon amide backbone.
  • PLA is isoelectronic with phenylalanine (Phe) but has no titratable hydrogen.
  • Tables 9 & 10 demonstrate that with the PLA6 substitution, the native Asp9 analog exhibits pure antagonism but the potency is reduced relative to that of the Glu9 and hCys(S0 3 H) 9 analogs.
  • the data presented in Table 12 demonstrates that the PLA6 substitution not only increases the peptide potency but also serves a critical role in pegylation.
  • the PLA6 analogs can be selectively pegylated without restoration of glucagon agonism.
  • the native Phe6 analogs surprisingly demonstrate a restoration of agonism when pegylated. However this restoration of agonism is not observed in the Pla6 peptide analogs.
  • Several specific pegylation sites were examined, including amino acid positions 8, 11 and 24 (relative to the native glucagon peptide). Pegylation at position 24 of the Pla6 analog exhibits the most potent and selective glucagon antagonism.
  • glucagon antagonists described herein are acylated as follows:
  • glucagon-based depsipeptides [Thr5-O-PLA6, E9]glucagon (2-29) amide and [Thr5-O-PLA6, E9]glucagon (1-29) amide were carried out as follows:
  • the peptidyl resin was treated with liquid hydrogen fluoride to cleave the crude peptide from the solid support and remove all protecting groups.
  • the depsipeptide was purified by preparative HPLC, and analyzed by MS and analytical HPLC.
  • the purified peptide demonstrated a single peak in analytical chromatography and the ESI-MS analysis yielded the desired mass of 3359.0 which corresponds with the calculated molecular weight of 3359.6 daltons.
  • the following peptides were synthesized as generally described above and subsequently tested for the ability to stimulate the GLP-1 receptor by assaying cAMP release from cells expressing the human GLP-1 receptor and for the ability to stimulate the glucagon receptor by assaying cAMP release from cells expressing the human glucagon receptor and stimulated with 0.5 nM glucagon, as generally described in Example 13. The results of the assays are shown in Table 13.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Claims (12)

  1. Antagoniste de glucagon comprenant la séquence de SEQ ID NO: 42, ou un dérivé de SEQ ID NO: 42 qui diffère de SEQ ID NO: 42 par des substitutions d'acide aminé à une à trois positions d'acide aminé choisies parmi les positions 5, 6, 8, 9, 12, 13, et 14 de SEQ ID NO: 42, le NH2 N-terminal de l'antagoniste de glucagon ou dérivé étant remplacé par un groupe hydroxyle de sorte que le Phe à la position 1 de l'antagoniste de glucagon soit l'acide phényl-lactique (PLA), et des sels pharmaceutiquement acceptables de celui-ci.
  2. Antagoniste de glucagon de la revendication 1, dans lequel, lorsque l'antagoniste de glucagon comprend la séquence de SEQ ID NO: 42 :
    (i) l'acide aminé terminal de l'antagoniste de glucagon a un groupe amide à la place du groupe acide carboxylique qui est présent sur l'acide aminé natif,
    (ii) l'acide aminé à la position 4 de SEQ ID NO: 42 est l'acide aspartique,
    (iii) l'antagoniste de glucagon comprend en outre l'acide aminé de SEQ ID NO: 19 fusionné à l'acide aminé carboxy-terminal de SEQ ID NO: 42,
    (iv) l'antagoniste de glucagon comprend en outre un fragment hydrophile lié de façon covalente à un résidu d'acide aminé à la position 11, 16, ou 19 de SEQ ID NO: 42, et des sels pharmaceutiquement acceptables dudit peptide de glucagon,
    (v) l'antagoniste de glucagon comprend la séquence de SEQ ID NO: 46 ou 47,
    (vi) lorsque l'acide aminé à la position 23 est Asn, l'acide aminé à la position 24 est choisi dans le groupe constitué de Asp ou Glu, et, lorsque l'acide aminé à la position 24 est Thr, l'acide aminé à la position 23 est choisi dans le groupe constitué de Asp ou Glu (selon la numérotation de SEQ ID NO: 42),
    (vii) l'antagoniste de glucagon comprend en outre un à deux acides aminés ajoutés à la terminaison carboxy de l'antagoniste de glucagon de SEQ ID NO: 42, lesdits acides aminés ajoutés à la terminaison carboxy étant indépendamment choisis dans le groupe constitué de Asp ou Glu,
    (viii) l'acide aminé à la position 10 de SEQ ID NO: 42 est choisi dans le groupe constitué de Glu, acide cystéique, acide homoglutamique, et acide homocystéique,
    (ix) l'antagoniste de glucagon comprend la séquence de l'un quelconque de SEQ ID NO: 7, 8, 36, 37, 39, 40, et 41.
  3. Antagoniste de glucagon de la revendication 1, dans lequel le fragment hydrophile est une protéine plasmatique ou la partie Fc d'un immunoglobuline, ou un polyéthylèneglycol, ou un polyéthylèneglycol qui a un poids moléculaire d'au moins environ 20 000 Daltons ou un poids moléculaire choisi dans la plage d'environ 1 000 à environ 5 000 daltons.
  4. Antagoniste de glucagon de la revendication 3, l'antagoniste de glucagon ayant la séquence de l'un quelconque de SEQ ID NO: 9-12, 16-18, et 43-45.
  5. Antagoniste de glucagon comprenant la structure générale de A-B-C, dans laquelle
    A est l'acide phényl-lactique (PLA) ;
    B représente les acides aminés 7 à 26 de SEQ ID NO: 1 comprenant une ou plusieurs modifications d'acide aminé choisies dans le groupe constitué de :
    (iv) Asp à la position 9 (selon la numérotation d'acides aminés de SEQ ID NO: 1) est substitué par un Glu, un dérivé d'acide sulfonique de Cys, un acide homoglutamique, un acide β-homoglutamique, ou un dérivé alkylcarboxylate de cystéine ayant la structure de :
    Figure imgb0109
     dans laquelle X5 est alkyle en C1-C4, alcényle en C2-C4, ou alcynyle en C2-C4,
    (v) substitution d'un ou deux acides aminés aux positions 10, 20, et 24 (selon la numérotation d'acides aminés de SEQ ID NO: 1) avec un acide aminé lié de façon covalente à un groupe acyle ou alkyle via un lieur ester, éther, thioéther, amide, ou alkylamine ;
    (vi) substitution d'un ou deux acides aminés aux positions 16, 17, 20, 21, et 24 (selon la numérotation d'acides aminés de SEQ ID NO: 1) avec un acide aminé choisi dans le groupe constitué de : Cys, Lys, ornithine, homocystéine, et acétyl-phénylalanine (Ac-Phe), l'acide aminé du groupe étant lié de façon covalente à un fragment hydrophile ;
    (vii) Asp à la position 15 (selon la numérotation de SEQ ID NO: 1) est substitué par un acide cystéique, un acide glutamique, un acide homoglutamique, et un acide homocystéique ;
    (viii) Ser à la position 16 (selon la numérotation de SEQ ID NO: 1) est substitué par un acide cystéique, un acide glutamique, un acide homoglutamique, et un acide homocystéique ;
    (ix) substitution par AIB à une ou plusieurs des positions 16, 20, 21, et 24 selon la numérotation d'acides aminés de SEQ ID NO: 1 ;
    et
    C est choisi dans le groupe constitué de :
    (x) X ;
    (xi) X-Y ;
    (xii) X-Y-2 ; et
    (xiii) X-Y-Z-R10,
    où X est Met, Leu, ou Nle ; Y est Asn ou un acide aminé chargé ; Z est Thr, Gly, Cys, Lys, ornithine (Orn), homocystéine, acétyle phénylalanine (Ac-Phe), ou un acide aminé chargé ; où R10 est choisi dans un groupe constitué de SEQ ID NO: 19-21 et 53 ; et
    (xiv) l'un quelconque de (x) à (xiii) dans lequel le carboxylate C-terminal est remplacé par un amide ou un sel pharmaceutiquement acceptable de celui-ci.
  6. Antagoniste de glucagon de la revendication 5, dans lequel : (A) lorsque Y ou Z est un acide aminé chargé, l'acide aminé chargé est choisi dans un groupe constitué de : Lys, Arg, His, Asp, et Glu, ou (B) l'antagoniste de glucagon comprend en outre un à deux acides aminés chargés C-terminaux pour Z, lorsque C comprend X-Y-Z.
  7. Antagoniste de glucagon de la revendication 5 ou 6, dans lequel B comprend la modification d'acide aminé désignée par (v) ou (vi), ou une combinaison de celles-ci.
  8. Antagoniste de glucagon de la revendication 7, dans lequel B comprend en outre une ou plusieurs modifications d'acide aminé choisies dans le groupe constitué de (iv), (vii), (viii), (ix), et une combinaison de celles-ci.
  9. Antagoniste de glucagon de l'une quelconque des revendications 5 à 8, comprenant (A) un fragment hydrophile lié de façon covalente à un résidu d'acide aminé à la position 16, 21, ou 24 selon la numérotation de SEQ ID NO: 1, ou le résidu N- ou C-terminal de l'antagoniste de glucagon ou (B) un acide aminé lié de façon covalente à un groupe acyle ou un groupe alkyle via un lieur ester, éther, thioéther, amide, ou alkylamine, l'acide aminé étant à la position 10, 20, ou 24 (selon la numérotation d'acides aminés de SEQ ID NO: 1), ou est le résidu N- ou C-terminal de l'antagoniste de glucagon ou (C) à la fois (A) et (B).
  10. Dimère ou multimère comprenant deux antagonistes de glucagon ou plus de l'une quelconque des revendications 1, 2, 3, 4, 5, 6, 7, 8, et 9, ou un conjugué comprenant un antagoniste de glucagon de l'une quelconque des revendications 1, 2, 3, 4, 5, 6, 7, 8, et 9, et un peptide hétérologue.
  11. Composition pharmaceutique stérile comprenant un antagoniste de glucagon de l'une quelconque des revendications 1, 2, 3, 4, 5, 6, 7, 8, et 9, un dimère ou multimère ou conjugué de la revendication 10, ou une combinaison de ceux-ci, et un véhicule pharmaceutiquement acceptable.
  12. Composition pour utilisation dans le traitement de l'hyperglycémie, la suppression de l'appétit, la réduction de la prise de poids, l'induction de la perte de poids, ou le traitement de la cachexie catabolique chez un patient, comprenant un peptide de l'une quelconque des revendications 1, 2, 3, 4, 5, 6, 7, 8, et 9, un dimère ou multimère ou conjugué de la revendication 10, ou une combinaison de ceux-ci.
EP08845852.6A 2007-10-30 2008-10-23 Antagonistes du glucagon Active EP2217701B9 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98378307P 2007-10-30 2007-10-30
PCT/US2008/080973 WO2009058662A2 (fr) 2007-10-30 2008-10-23 Antagonistes du glucagon

Publications (4)

Publication Number Publication Date
EP2217701A2 EP2217701A2 (fr) 2010-08-18
EP2217701A4 EP2217701A4 (fr) 2011-06-15
EP2217701B1 EP2217701B1 (fr) 2014-07-02
EP2217701B9 true EP2217701B9 (fr) 2015-02-18

Family

ID=40591715

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08845852.6A Active EP2217701B9 (fr) 2007-10-30 2008-10-23 Antagonistes du glucagon

Country Status (13)

Country Link
US (1) US8981047B2 (fr)
EP (1) EP2217701B9 (fr)
JP (1) JP5669582B2 (fr)
AR (1) AR069110A1 (fr)
AU (1) AU2008318986B2 (fr)
CA (1) CA2707861A1 (fr)
CL (1) CL2008003222A1 (fr)
ES (1) ES2509883T3 (fr)
HK (1) HK1143994A1 (fr)
MX (1) MX2010004297A (fr)
PE (1) PE20091393A1 (fr)
TW (1) TW200920404A (fr)
WO (1) WO2009058662A2 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2628241C (fr) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
AU2008205229B2 (en) 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CA2702289A1 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Composes presentant une activite d'antagoniste de glucagon et d'agoniste du glp-1
MX2010004297A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Antagonistas de glucagon.
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
CN104945500B (zh) 2008-06-17 2019-07-09 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
JP2012512903A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド系グルカゴンスーパーファミリーペプチドプロドラッグ
RU2012101274A (ru) * 2009-06-16 2013-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соединения глюкагона, активные в отношении рецептора gip
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8765728B2 (en) 2009-11-16 2014-07-01 Mellitech [1,5]-diazocin derivatives
WO2011075393A2 (fr) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon/glp-i
WO2011094337A1 (fr) * 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2552952A1 (fr) * 2010-03-26 2013-02-06 Novo Nordisk A/S Nouveaux analogues de glucagon
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
EP2569000B1 (fr) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire d'hormone
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012059762A1 (fr) 2010-11-03 2012-05-10 Arecor Limited Nouvelle composition comprenant du glucagon
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
PE20140724A1 (es) 2011-06-22 2014-07-10 Univ Indiana Res & Tech Corp Coagonistas del receptor de glucagon/glp-1
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
KR20140097151A (ko) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
EP2820038B1 (fr) 2012-03-01 2020-06-17 Novo Nordisk A/S Promédicaments glp-1
WO2013192129A1 (fr) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogues du glucagon présentant une activité sur le récepteur du gip
WO2014041375A1 (fr) * 2012-09-17 2014-03-20 Imperial Innovations Limited Analogues peptidiques du glucagon et du glp1
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014096150A1 (fr) 2012-12-21 2014-06-26 Sanofi Agonistes du glp1/gip double ou du glp1/gip/glucagon trigonal
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EP3080154B1 (fr) 2013-12-13 2018-02-07 Sanofi Agonistes doubles du récepteur glp-1/gip
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080152A1 (fr) 2013-12-13 2016-10-19 Sanofi Analogues peptidiques de l'exendine 4 non acylés
AR100306A1 (es) 2014-02-18 2016-09-28 Novo Nordisk As Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TW201625672A (zh) 2014-10-24 2016-07-16 默沙東藥廠 升糖素及ｇｌｐ－１受體之共促效劑
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
CN111670042A (zh) * 2017-12-07 2020-09-15 阿道恰公司 包含人胰高血糖素和共聚氨基酸的可注射水溶液形式的组合物

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275152A (en) 1977-02-03 1981-06-23 Eastman Kodak Company Hydrolysis of protein-bound cholesterol esters
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
NZ232562A (en) * 1989-02-17 1992-10-28 Coselco Mimotopes Pty Ltd Immobilised peptide - solid support comprising a cleavable ester link between the peptide carboxy terminus and the solid support
CA2024855C (fr) 1990-09-07 1997-12-09 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Procede et intermediaires pour la production du glucagon
JPH04145099A (ja) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
US5510459A (en) 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en) 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
EP0879279A4 (fr) 1996-02-06 2000-07-12 Lilly Co Eli Therapie des diabetes
IL128828A0 (en) 1996-09-09 2000-01-31 Zealand Pharmaceuticals As Peptide prodrugs containing an alpha-hydroxy acid linker
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
EP1062229A1 (fr) 1998-03-09 2000-12-27 Zealand Pharmaceuticals A/S Conjugues peptidiques pharmacologiquement actifs ayant une tendance reduite a l'hydrolyse enzymatique
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
WO2000020592A1 (fr) 1998-10-07 2000-04-13 Medical College Of Georgia Research Institute, Inc. Peptide glucodependant insulinotrope utilise comme hormone osteotrope
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
PT1171465E (pt) 1999-03-29 2004-12-31 Uutech Ltd Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US6458493B2 (en) * 1999-06-04 2002-10-01 International Business Machines Corporation Method to control nested to isolated line printing
EP1356295A2 (fr) 2000-04-27 2003-10-29 Bionebraska, Inc. Test de diagnostic de polypeptide inhibiteur gastrique destine a la detection de la sensibilite aux diabetes de type 2, a une intolerance au glucose, ou a une glycemie a jeun
US6677136B2 (en) * 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US20030021795A1 (en) 2000-06-14 2003-01-30 Houston Michael E. Use of coiled-coil structural scaffold to generate structure-specific peptides
DK1294757T3 (da) 2000-06-16 2007-03-19 Lilly Co Eli Glucagonlignende peptid 1-analoger
BR0113178A (pt) 2000-08-02 2004-04-06 Theratechnologies Inc Peptìdeos biológicos modificados com potência aumentada
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
DE60228972D1 (de) 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
AU2002327430A1 (en) 2001-08-08 2003-02-24 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
CN1635900A (zh) 2001-08-28 2005-07-06 伊莱利利公司 Glp－1和基础胰岛素的预混合物
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
EP1572892A4 (fr) 2001-10-18 2007-08-22 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
CN1571676A (zh) 2001-10-19 2005-01-26 伊莱利利公司 Glp－1和胰岛素的双相混合物
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
AU2003239478A1 (en) 2002-06-04 2003-12-22 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
AU2003237933A1 (en) 2002-06-11 2003-12-22 Cellartis Ab Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
US20040029805A1 (en) 2002-06-15 2004-02-12 Wolfe M. Michael Prevention and treatment of nonalcoholic fatty liver disease (NAFLD) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (GIP)
JP2006501820A (ja) 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
WO2004078777A2 (fr) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Proteines protegees contre la dipeptidylpeptidase
AU2004231461B2 (en) 2003-03-19 2009-11-12 Eli Lilly And Company Polyethelene glycol linked GLP-1 compounds
DK1620118T3 (da) 2003-04-08 2014-09-29 Yeda Res & Dev Reversible pegylerede lægemidler
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
EP1633384B1 (fr) 2003-05-15 2012-03-14 Trustees Of Tufts College Analogues stables de glp-1
CA2527743A1 (fr) 2003-06-03 2004-12-09 Novo Nordisk A/S Compositions pharmaceutiques peptidiques stabilisees
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
US20050124550A1 (en) 2003-06-18 2005-06-09 Peri Krishna G. Compounds that modulate the glucagon response and uses thereof
EP1670515A2 (fr) 2003-09-19 2006-06-21 Novo Nordisk A/S Derives de peptides therapeutiques liant l'albumine
US7364875B2 (en) 2003-10-30 2008-04-29 Cresent Innovations, Inc. Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
EP1704165B1 (fr) * 2003-12-18 2010-03-17 Novo Nordisk A/S Composes de glp-1
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
US20090062192A1 (en) 2005-03-18 2009-03-05 Novo Nordisk A/S Dimeric Peptide Agonists of the Glp-1 Receptor
WO2006121904A1 (fr) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Agonistes du recepteur du polypeptide insulinotropique gluco-dependant (gip) et procedes pharmacologiques d'utilisation associes
ATE482724T1 (de) 2005-05-13 2010-10-15 Lilly Co Eli Pegylierte glp-1-verbindungen
KR101349808B1 (ko) 2005-06-13 2014-02-13 임페리얼 이노베이션스 리미티드 섭취행동에 관한 신규 화합물들 및 이들의 효능
CA2617649A1 (fr) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Polypeptides hybrides presentant des proprietes selectionnables
EP1943274A2 (fr) 2005-09-08 2008-07-16 Uutech Limited Traitement de l'obesite associee aux diabetes
AU2006289259A1 (en) 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
CA2628241C (fr) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
EP2471811B1 (fr) 2006-02-22 2015-09-16 Merck Sharp & Dohme Corp. Dérivés d'oxyntomoduline
EP2241327A1 (fr) 2006-03-15 2010-10-20 Novo Nordisk A/S Melange d'amyline et d'insuline
JP5412273B2 (ja) 2006-03-21 2014-02-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー ペプチド−ぺプチダーゼ阻害剤及びその使用
WO2008022015A2 (fr) 2006-08-11 2008-02-21 Trustees Of Tufts College Analogues rétro-inverso de l'incrétine, et procédés pour leur utilisation
WO2008021560A2 (fr) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Analogue du gip et polypeptides hybrides possédant des propriétés sélectives
WO2008023050A1 (fr) 2006-08-25 2008-02-28 Novo Nordisk A/S Composés d'exendine-4 acylée
EP2102355B1 (fr) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Protéines et peptides à action prolongée et procédés de production et d'utilisation de ces derniers
AU2008205229B2 (en) 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
AU2008216265B2 (en) * 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN101842386A (zh) 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
EP2190872B1 (fr) 2007-09-05 2018-03-14 Novo Nordisk A/S Dérivés de glucagon-like peptide-1 et leur utilisation pharmaceutique
WO2009035540A2 (fr) 2007-09-07 2009-03-19 Ipsen Pharma S.A.S. Analogues d'exendine-4 et exendine-3
WO2009034117A1 (fr) 2007-09-11 2009-03-19 Novo Nordisk A/S Mélange comprenant de l'amyline, qui est un peptide, et une insuline retard
EP2036923A1 (fr) 2007-09-11 2009-03-18 Novo Nordisk A/S Dérivés d'amyline améliorés
EP2036539A1 (fr) 2007-09-11 2009-03-18 Novo Nordisk A/S Formulations stables d'amyline et ses analogues
CA2702289A1 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Composes presentant une activite d'antagoniste de glucagon et d'agoniste du glp-1
MX2010004297A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Antagonistas de glucagon.
US8261025B2 (en) 2007-11-12 2012-09-04 International Business Machines Corporation Software pipelining on a network on chip
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
CA2712224C (fr) 2008-02-01 2016-03-08 Ascendis Pharma As Promedicament comprenant un conjugue medicament-lieur
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CN104945500B (zh) 2008-06-17 2019-07-09 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
JP2012512903A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド系グルカゴンスーパーファミリーペプチドプロドラッグ
JP2012512898A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション ジペプチド結合薬用剤
WO2010096052A1 (fr) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Analogues d'oxyntomoduline
RU2012101274A (ru) 2009-06-16 2013-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соединения глюкагона, активные в отношении рецептора gip
WO2011075393A2 (fr) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon/glp-i
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
WO2011094337A1 (fr) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
EP2569000B1 (fr) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire d'hormone
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
WO2011163473A1 (fr) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Analogues du glucagon présentant une solubilité et une stabilité améliorées dans des tampons à ph physiologique

Also Published As

Publication number Publication date
MX2010004297A (es) 2010-05-03
EP2217701B1 (fr) 2014-07-02
JP5669582B2 (ja) 2015-02-12
EP2217701A4 (fr) 2011-06-15
JP2011502155A (ja) 2011-01-20
HK1143994A1 (en) 2011-01-21
AR069110A1 (es) 2009-12-30
WO2009058662A2 (fr) 2009-05-07
US20120122783A1 (en) 2012-05-17
CL2008003222A1 (es) 2009-02-27
AU2008318986B2 (en) 2014-12-04
TW200920404A (en) 2009-05-16
CA2707861A1 (fr) 2009-05-07
PE20091393A1 (es) 2009-09-11
AU2008318986A1 (en) 2009-05-07
US8981047B2 (en) 2015-03-17
EP2217701A2 (fr) 2010-08-18
ES2509883T3 (es) 2014-10-20
WO2009058662A3 (fr) 2010-01-07

Similar Documents

Publication Publication Date Title
EP2217701B9 (fr) Antagonistes du glucagon
US8980830B2 (en) Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
AU2009210570B2 (en) Ester-based insulin prodrugs
EP3206710B1 (fr) Conjugués d'insuline-incrétines
RU2580317C2 (ru) Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
US8969288B2 (en) Amide based glucagon and superfamily peptide prodrugs
US20160058881A1 (en) Prodrugs with prolonged action
TW201103556A (en) GIP receptor-active glucagon compounds
JP2019520336A (ja) 水溶性で化学的に安定なグルカゴンペプチド

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100527

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1143994

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110517

17Q First examination report despatched

Effective date: 20120813

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140207

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOHEST AG, CH

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 675956

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH)

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008033138

Country of ref document: DE

Effective date: 20140814

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1143994

Country of ref document: HK

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2509883

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20141020

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 675956

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140702

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140702

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141002

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141002

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141003

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141103

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141102

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008033138

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141023

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

26N No opposition filed

Effective date: 20150407

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141031

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140702

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20081023

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20161027

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20161010

Year of fee payment: 9

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20181029

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20181102

Year of fee payment: 11

Ref country code: GB

Payment date: 20181029

Year of fee payment: 11

Ref country code: IT

Payment date: 20181023

Year of fee payment: 11

Ref country code: FR

Payment date: 20181025

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008033138

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200501

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20191023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191023

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191024